

advances.sciencemag.org/cgi/content/full/6/19/eaba0946/DC1

Supplementary Materials for

Bioinspired design of a robust d_3 -methylating agent

Minyan Wang, Yunfei Zhao, Yue Zhao, Zhuangzhi Shi*

*Corresponding author. Email: shiz@nju.edu.cn


Published 8 May 2020, *Sci. Adv.* **6**, eaba0946 (2020)

DOI: [10.1126/sciadv.aba0946](https://doi.org/10.1126/sciadv.aba0946)

This PDF file includes:

Sections S1 to S10


Section S1. The synthesis of trideuteromethyl reagent DMTT



According to our patent, to a 50 mL round flask was added formic acid (7.8 mL, 150 mmol, 3 equiv, 88 wt.% aqueous solution), CD_3OD (20.2 mL, 500 mmol, 10 equiv, $d = 0.89\text{ g/mL}$, 99% D). Then sulphuric acid (8.8 mL, 165 mmol, 11 equiv, 98%) was added dropwise to the above solution with stirring. The reaction was heated at $60\text{ }^\circ\text{C}$ and stirring for 4 h. The methyl- d_3 formate containing a small amount of deuterated methanol was directly distilled at atmospheric pressure ($33\text{-}38\text{ }^\circ\text{C}$). The methyl- d_3 formate was used without further purification.


A 50 mL round flask was charged with dibenzothiophene (9.2 g, 50 mmol, 1 equiv) and above distilled methyl- d_3 formate. The mixture was stirred at $0\text{ }^\circ\text{C}$ and Tf_2O (20 mL) was dropwise with stirring. Then the reaction was heated up to $60\text{ }^\circ\text{C}$. When the mixture became a clear solution, the reaction was poured into water (100 mL), extracted with CH_2Cl_2 (50 mL \times 3), dried with MgSO_4 , and concentrated in vacuo. The obtained crude product was washed with Et_2O (50 mL \times 3) and dried under vacuum to afford the trideuteromethyl reagent **DMTT** (16.0 g, 91%, 99% D).

5-(Methyl- d_3)-5H-dibenzo[*b,d*]thiophen-5-ium trifluoromethanesulfonate **DMTT**:




$^1\text{H NMR}$ (500 MHz, CD_3CN) δ 8.30 - 8.22 (m, 4 H), 7.93 - 7.85 (m, 2 H), 7.78 - 7.70 (m, 2 H). $^{13}\text{C NMR}$ (126 MHz, CD_3CN) δ 140.2, 134.9, 132.0, 131.5, 128.6, 125.1. ATR-FTIR (cm^{-1}): 3097, 3049, 2944, 1420, 1257, 1160, 1033, 755, 641. HRMS (ESI^+) Calcd for $\text{C}_{13}\text{H}_8\text{D}_3\text{S} [\text{M-OTf}]^+$: 202.0764, found: 202.0767.

The corresponding non-deuterated product **MTT**:




^1H NMR (500 MHz, CD_3CN) δ 8.30 - 8.20 (m, 4 H), 7.93 - 7.84 (m, 2 H), 7.78 - 7.68 (m, 2 H), 3.33 (s, 3 H). ^{13}C NMR (126 MHz, CD_3CN) δ 140.1, 134.8, 131.9, 131.6, 128.6, 125.1, 35.0.

Section S2. Reaction development



To a Schlenk tube was added carboxylic acid **1a** (0.2 mmol, 1.0 equiv), CD_3 source, base (0.4 mmol, 2.0 equiv), and MeCN (2 mL). The reaction was stirring at room temperature for 12 h. Then the resulting mixture was concentrated in vacuo and the residue was purified by column chromatography to afford the corresponding product **1b** and side products **1c**, **1d**, and **1e**.


Methyl- d_3 4-(dimethylamino)benzoate (**1b**)




The reaction of 4-(dimethylamino)benzoic acid **1a** (27.4 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **1b** (32.7 mg, 90%, 99% D) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 7.95 - 7.86 (m, 2 H), 6.68 - 6.59 (m, 2 H), 3.03 (s, 6 H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.4, 153.2, 131.2, 116.9, 110.6, 40.0.

ATR-FTIR (cm⁻¹): 2948, 2903, 2824, 1702, 1620, 1436, 1284, 1190, 1133, 914, 828, 770, 743. HRMS (ESI⁺) Calcd for C₁₀H₁₁D₃NO₂ [M+H]⁺: 183.1207, found: 183.1207.


The corresponding non-deuterated product:




4-((Methoxy-*d*₃)carbonyl)-*N,N*-dimethyl-*N*-(methyl-*d*₃)benzenaminium (**1c**)



The corresponding non-deuterated product:




4-(methoxycarbonyl)-*N*-methyl-*N,N*-bis(methyl-*d*₃)benzenaminium (**1d**)




(m, 2 H), 3.86 (s, 3 H), 3.68 (s, 3 H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ 164.9, 150.4, 130.9, 130.7, 121.6, 56.4, 52.8. ATR-FTIR (cm^{-1}): 2948, 2933, 1719, 1658, 1295, 1010, 823, 761. HRMS (ESI^+) Calcd for $\text{C}_{11}\text{H}_{10}\text{D}_6\text{NO}_2$ $[\text{M}]^+$: 200.1552, found: 200.1555.

Section S3. Further investigations of compound **2a** with DMTT reagent.




To a Schlenk tube was added carboxylic acid **2a** (30.6 mg, 0.2 mmol, 1.0 equiv), CD_3I (62.2 μL , $d = 2.33$ g/mL, 1.0 mmol, 5.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL). The reaction was stirring at room temperature for 12 h. Then the resulting mixture was concentrated in vacuo and the residue was purified by column chromatography to afford the byproduct **2b** (white solid, 8.9 mg, 26%, 99% D), **2c** (white solid, 6.7 mg, 18%, 99% D), and **2d** (white solid, 5.0 mg, 20%, 99% D).

Methyl- d_3 4-amino-2-hydroxybenzoate (**2b**)



ATR-FTIR (cm^{-1}): 3474, 3380, 3247, 2928, 1653, 1623, 1517, 1436, 1355, 1285, 1190, 1153, 1080, 914, 780, 749. HRMS (ESI^+) Calcd for $\text{C}_8\text{H}_7\text{D}_3\text{NO}_3$ $[\text{M}+\text{H}]^+$: 171.0843, found: 171.0843.

The corresponding non-deuterated product:




Methyl 4-amino-2-hydroxybenzoate **2b-H** (CAS: 4136-97-4):

^1H NMR (400 MHz, CDCl_3) δ 10.93 (s, 1 H), 7.71 - 7.51 (m, 1 H), 6.23 - 6.01 (m, 2 H), 4.09 (s, 2 H), 3.87 (s, 3 H). ^{13}C

NMR (101 MHz, CDCl_3) δ 170.4, 163.6, 153.3, 131.6, 106.8, 103.0, 100.7, 51.7.


Methyl- d_3 2-hydroxy-4-((methyl- d_3)amino)benzoate (**2c**)



^1H NMR (400 MHz, CDCl_3) δ 11.01 (s, 1 H), 7.59 (d, J = 8.6 Hz, 1 H), 6.23 - 5.90 (m, 2 H), 4.19 (s, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.6, 163.8, 155.3, 131.1, 105.4,

101.6, 97.2. ATR-FTIR (cm^{-1}): 3415, 2993, 2948, 1680, 1635, 1528, 1349, 1282, 1149, 914, 749. HRMS (ESI $^+$) Calcd for $\text{C}_9\text{H}_6\text{D}_6\text{NO}_3$ [$\text{M}+\text{H}$] $^+$: 188.1188, found: 188.1185.


The corresponding non-deuterated product:



Methyl 2-hydroxy-4-(methylamino)benzoate **2c-H** (CAS: 1175090-85-3): ^1H NMR (400 MHz, CDCl_3) δ 11.00 (s, 1 H), 7.59 (d, J = 8.5 Hz, 1 H), 6.20 - 5.97 (m, 2 H), 4.21 (s,

1 H), 3.87 (s, 3 H), 2.86 (d, J = 5.0 Hz, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 131.1, 105.4, 97.2, 51.6, 30.0.


Methyl- d_3 4-(bis(methyl- d_3)amino)-2-hydroxybenzoate (**2d**)



^1H NMR (400 MHz, CDCl_3) δ 10.92 (s, 1 H), 7.64 (d, J = 9.0 Hz, 1 H), 6.20 (dd, J = 9.0, 2.5 Hz, 1 H), 6.13 (d, J = 2.5 Hz, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 163.2, 131.0, 104.0, 97.7. ATR-FTIR (cm^{-1}): 3392, 2994, 2951, 1706,

1653, 1541, 1340, 1296, 914, 744. HRMS (ESI $^+$) Calcd for $\text{C}_{10}\text{H}_5\text{D}_9\text{NO}_3$ [$\text{M}+\text{H}$] $^+$: 205.1533, found: 205.1534.


The corresponding non-deuterated product:



Methyl 4-(dimethylamino)-2-hydroxybenzoate **2d-H** (CAS: 27559-59-7): ^1H NMR (400 MHz, CDCl_3) δ 10.91 (s, 1 H), 7.64 (d, $J = 9.0$ Hz, 1 H), 6.21 (dd, $J = 9.0, 2.6$ Hz, 1 H), 6.14 (d, $J = 2.6$ Hz, 1 H), 3.88 (s, 3 H), 3.02 (s, 6 H). ^{13}C NMR (101 MHz, CDCl_3) δ 130.9, 104.0, 97.8, 51.5, 40.0.


Section S4. The synthesis of products **b**

General Procedure A:



To a Schlenk tube was added carboxylic acid **a** (0.2 mmol, 1.0 equiv), **DMTT**, K_2CO_3 , and MeCN (2 mL). The reaction was stirring at room temperature for 12 h. Then the resulting mixture was concentrated in vacuo and the residue was purified by column chromatography to afford the corresponding product **b**.


Methyl- d_3 2-cyclopentyl-2-hydroxy-2-phenylacetate (**3b**)



Following the general procedure A, the reaction of **3a** (44.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **3b** (46.9 mg, 99%, 99% D) as a colorless oil: ^1H NMR (400 MHz, CDCl_3) δ 7.69 - 7.60 (m, 2 H), 7.38 - 7.29 (m, 2 H), 7.29 - 7.22 (m, 1 H), 3.74 (s, 1 H), 2.95 - 2.85 (m, 1 H), 1.73 - 1.40 (m, 6 H), 1.39 - 1.29 (m, 2H). ^{13}C NMR (101 MHz, CDCl_3) δ 176.1, 141.7, 128.0, 127.4, 125.9, 79.2, 47.2, 26.9, 26.31, 26.25, 25.9. ATR-FTIR (cm^{-1}): 3512, 2954, 2868, 1725, 1445, 1253,

1173, 740, 698. HRMS (ESI⁺) Calcd for C₁₄H₁₅D₃O₃Na [M+Na]⁺: 260.1336, found: 260.1333.


The corresponding non-deuterated product:



3b-H

Methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate **3b-H** (CAS: 19833-96-6): ¹H NMR (400 MHz, CDCl₃) δ 7.68 - 7.61 (m, 2 H), 7.37 - 7.30 (m, 2 H), 7.29 - 7.23 (m, 1 H), 3.76 (s, 3 H), 3.73 (d, *J* = 0.7 Hz, 1 H), 2.95 - 2.85 (m, 1 H), 1.73 - 1.40 (m, 6 H), 1.38 - 1.29 (m, 2H). ¹³C NMR (101 MHz, CDCl₃) δ 176.1, 141.7, 128.0, 127.4, 125.9, 79.2, 53.2, 47.2, 26.9, 26.33, 26.26, 25.9.


Methyl-*d*₃ 4-aminobenzoate (**4b**)



4b

Following the general procedure A, the reaction of **4a** (27.4 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K₂CO₃ (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **4b** (21.6 mg, 70%, 99% D) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, *J* = 8.7 Hz, 2 H), 6.63 (d, *J* = 8.7 Hz, 2 H), 4.09 (bs, 2 H). ¹³C NMR (101 MHz, CDCl₃) δ 167.2, 150.8, 131.5, 119.6, 113.7. ATR-FTIR (cm⁻¹): 3676, 3080, 1685, 1508, 1457, 1288, 773, 669. HRMS (ESI⁺) Calcd for C₈H₇D₃NO₂ [M+H]⁺: 155.0894, found: 155.0890.


The corresponding non-deuterated product:



4b-H

Methyl 4-aminobenzoate **4b-H** (CAS: 619-45-4): ¹H NMR (400 MHz, CDCl₃) δ 7.84 (d, *J* = 8.7 Hz, 2 H), 6.63 (d, *J* = 8.7 Hz, 2 H), 4.07 (bs, 2 H), 3.85 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ 167.2, 150.8, 131.6, 119.7, 113.8, 51.6.


Methyl-*d*₃ 2-(1*H*-indol-3-yl)acetate (**5b**)



5b

Following the general procedure A, the reaction of **5a** (35.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **5b** (32.3 mg, 84%, 99% D) as a colorless oil: 1H NMR (400 MHz, $CDCl_3$) δ 8.16 (s, 1 H), 7.66 - 7.61 (m, 1 H), 7.35 - 7.31 (m, 1 H), 7.25 - 7.13 (m, 2 H), 7.12 - 7.08 (m, 1 H), 3.81 (d, $J = 0.9$ Hz, 2 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 172.6, 136.1, 127.2, 123.1, 122.2, 119.7, 118.8, 111.2, 108.3, 31.1. ATR-FTIR (cm^{-1}): 3408, 2950, 1720, 1456, 1431, 1163, 1094, 1007, 743, 587. HRMS (ESI⁺) Calcd for $C_{11}H_8D_3NO_2Na$ [$M+Na$]⁺: 215.0870, found: 215.0872.


The corresponding non-deuterated product:



5b-H

Methyl 2-(1*H*-indol-3-yl)acetate **5b-H** (CAS: 1912-33-0): 1H NMR (400 MHz, $CDCl_3$) δ 8.14 (s, 1 H), 7.67 - 7.58 (m, 1 H), 7.37 - 7.31 (m, 1 H), 7.24 - 7.15 (m, 2 H), 7.14-7.11 (m, 1 H), 3.80 (d, $J = 0.9$ Hz, 2 H), 3.72 (s, 3 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 172.6, 136.1, 127.2, 123.1, 122.2, 119.6, 118.8, 111.2, 108.3, 52.0, 31.1.


Methyl-*d*₃ (tert-butoxycarbonyl)valinate (**6b**)



6b

Following the general procedure A, the reaction of **6a** (43.4 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **6b** (41.5 mg, 89%, 99% D) as a colorless oil: 1H NMR (400 MHz, $CDCl_3$) δ 5.02 (d, $J = 9.2$ Hz, 1 H), 4.20 (dd, $J = 9.2, 4.9$ Hz, 1 H), 2.17 - 2.02 (m, 1 H), 1.42 (s, 9 H), 0.93 (d, $J = 6.8$ Hz, 3 H), 0.87 (d, $J = 6.9$ Hz, 3 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 172.9, 155.6, 79.7, 58.5, 31.3, 28.3, 18.9, 17.6. ATR-FTIR (cm^{-1}): 3369, 2970, 2880, 1715, 1504, 1366, 1163, 1014. HRMS (ESI⁺) Calcd for $C_{11}H_{18}D_3NO_4Na$ [$M+Na$]⁺: 257.1551, found: 257.1552.


The corresponding non-deuterated product:



Methyl (tert-butoxycarbonyl)valinate **6b-H** (CAS: 145618-65-1): ^1H NMR (400 MHz, CDCl_3) δ 5.02 (d, $J = 9.2$ Hz, 1 H), 4.20 (dd, $J = 9.2, 4.9$ Hz, 1 H), 3.72 (s, 3 H), 2.16 - 2.04 (m, 1 H), 1.43 (s, 9 H), 0.94 (d, $J = 6.9$ Hz, 3 H), 0.87 (d, $J = 6.9$ Hz, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 172.9, 155.6, 79.7, 58.5, 52.0, 31.3, 28.3, 18.9, 17.6.


Methyl- d_3

(*E*)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (**7b**)



Following the general procedure A, the reaction of **7a** (64.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **7b** (58.3 mg, 86%, 99% D) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 7.65 (s, 1 H), 5.27 - 5.19 (m, 1 H), 5.18 (s, 2 H), 3.74 (s, 3 H), 3.36 (d, $J = 7.0$ Hz, 2 H), 2.42 - 2.34 (m, 2 H), 2.32 - 2.24 (m, 2 H), 2.13 (s, 3 H), 1.78 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 173.8, 172.8, 163.6, 153.5, 143.9, 134.1, 122.7, 122.0, 116.7, 106.3, 70.0, 60.9, 34.5, 32.8, 22.5, 16.0, 11.5. ATR-FTIR (cm^{-1}): 3428, 2947, 2852, 1707, 1625, 1454, 1367, 1136, 1076, 1030, 970. HRMS (ESI^+) Calcd for $\text{C}_{18}\text{H}_{20}\text{D}_3\text{O}_6$ [$\text{M}+\text{H}$] $^+$: 338.1677, found: 338.1677.

The corresponding non-deuterated product:




Methyl (*E*)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate **7b-H** (CAS: 31858-66-9): ^1H NMR (400 MHz, CDCl_3) δ 7.65 (s, 1 H), 5.26 - 5.19 (m, 1 H), 5.17 (s, 2 H), 3.74 (s, 3 H), 3.59 (s, 3 H), 3.36 (d, $J = 7.0$ Hz, 2 H), 2.42 - 2.34 (m, 2 H), 2.31 - 2.24 (m, 2 H), 2.13 (s, 3 H), 1.78

(s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 173.8, 172.9, 163.6, 153.6, 144.0, 134.1, 122.7, 122.1, 116.7, 106.3, 70.0, 61.0, 51.4, 34.6, 32.8, 22.6, 16.1, 11.5.

Methyl- d_3


(*R*)-4-((3*R*,5*S*,8*R*,9*S*,10*S*,13*R*,14*S*,17*R*)-3-hydroxy-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl)pentanoate (**8b**)



Following the general procedure A, the reaction of **8a** (75.2 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **8b** (63.8 mg, 81%, 99% D) as a white solid: ^1H NMR (400

MHz, CDCl_3) δ 3.68 - 3.48 (m, 1 H), 2.38 - 2.27 (m, 1 H), 2.25 - 2.14 (m, 1 H), 1.97 - 1.90 (m, 1 H), 1.90 - 1.70 (m, 6 H), 1.69 - 1.59 (m, 1 H), 1.59 - 1.44 (m, 2 H), 1.44 - 1.17 (m, 11 H), 1.17 - 0.93 (m, 6 H), 0.92 - 0.86 (m, 6 H), 0.62 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 174.8, 71.7, 56.4, 55.9, 42.7, 42.0, 40.4, 40.1, 36.4, 35.8, 35.3, 34.5, 31.0, 30.9, 30.5, 28.1, 27.1, 26.4, 24.1, 23.3, 20.8, 18.2, 12.0. ATR-FTIR (cm^{-1}): 3344, 2900, 2863, 1740, 1448, 1373, 1167, 1038. HRMS (ESI $^+$) Calcd for $\text{C}_{25}\text{H}_{39}\text{D}_3\text{O}_3\text{Na}$ [$\text{M}+\text{Na}$] $^+$: 416.3214, found: 416.3216.

The corresponding non-deuterated product:




Methyl
(*R*)-4-((3*R*,5*S*,8*R*,9*S*,10*S*,13*R*,14*S*,17*R*)-3-hydroxy-10,13-dimethylhexadecahydro-1*H*-cyclopenta[*a*]phenanthren-17-yl)pentanoate **8b-H** (CAS: 1249-75-8): ^1H NMR (400 MHz, CDCl_3) δ 3.64 (s, 3 H), 3.63 - 3.54 (m, 1 H), 2.40 - 2.27 (m, 1 H), 2.27 - 2.13 (m, 1 H), 1.99 - 1.89 (m, 1 H), 1.90 - 1.68 (m, 6 H), 1.69 - 1.58 (m, 1 H), 1.59 - 1.45 (m, 2 H), 1.44 - 1.16 (m, 11 H), 1.17 - 0.93 (m, 6 H), 0.93 - 0.85 (m, 6

H), 0.62 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 174.7, 71.7, 56.4, 55.9, 51.4, 42.7, 42.0, 40.4, 40.1, 36.4, 35.8, 35.3, 34.5, 31.0, 30.9, 30.5, 28.1, 27.1, 26.4, 24.2, 23.3, 20.8, 18.2, 12.0.

Methyl- d_3


(2*S*,4*aS*,6*aS*,6*bR*,8*aR*,10*S*,12*aS*,12*bR*,14*bR*)-10-hydroxy-2,4*a*,6*a*,6*b*,9,9,12*a*-heptamethyl-13-oxo-1,2,3,4,4*a*,5,6,6*a*,6*b*,7,8,8*a*,9,10,11,12,12*a*,12*b*,13,14*b*-icosahydricene-2-carboxylate (**9b**)



Following the general procedure A, the reaction of **9a** (94.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **9b** (93.9 mg, 96%, 99% D) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 5.62 (s, 1 H), 3.24 - 3.12 (m, 1 H),

2.81 - 2.68 (m, 1 H), 2.30 (s, 1 H), 2.08 - 1.72 (m, 6 H), 1.65 - 1.54 (m, 5 H), 1.40 - 1.24 (m, 8 H), 1.18 - 1.06 (m, 11 H), 1.02 - 0.90 (m, 4 H), 0.77 (s, 6 H), 0.66 (d, J = 11.5 Hz, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 200.2, 176.9, 169.1, 128.4, 78.6, 61.7, 54.8, 48.3, 45.3, 43.9, 43.1, 41.0, 39.0, 37.7, 37.0, 32.7, 31.7, 31.0, 28.4, 28.2, 28.0, 27.2, 26.4, 26.3, 23.3, 18.6, 17.4, 16.3, 15.5. ATR-FTIR (cm^{-1}): 3343, 2942, 2870, 1723, 1657, 1461, 1386, 1215, 1160, 1042, 913, 741. HRMS (ESI⁺) Calcd for $\text{C}_{31}\text{H}_{45}\text{D}_3\text{O}_4\text{Na}$ [$\text{M}+\text{Na}$]⁺: 510.3633, found: 510.3628.

The corresponding non-deuterated product:




Methyl
(2*S*,4*aS*,6*aS*,6*bR*,8*aR*,10*S*,12*aS*,12*bR*,14*bR*)-10-hydroxy-2,4*a*,6*a*,6*b*,9,9,12*a*-heptamethyl-13-oxo-1,2,3,4,4*a*,5,6,6*a*,6*b*,7,8,8*a*,9,10,11,12,12*a*,12*b*,13,14*b*-icosahydricene-2-carboxylate **9b-H** (CAS: 1477-44-7): ^1H NMR (400 MHz, CDCl_3) δ 5.63 (s, 1 H), 3.66 (s, 3 H), 3.27 - 3.13

(m, 1 H), 2.84 - 2.70 (m, 1 H), 2.31 (s, 1 H), 2.11 - 1.72 (m, 6 H), 1.69 - 1.52 (m, 5 H), 1.45 - 1.26 (m, 8 H), 1.20 - 1.06 (m, 10 H), 1.03 - 0.90 (m, 5 H), 0.78 (s, 6 H), 0.67 (d, $J = 11.9$ Hz, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 200.2, 176.9, 169.1, 128.5, 78.7, 61.7, 54.9, 51.7, 48.3, 45.3, 44.0, 43.1, 41.0, 39.1, 37.7, 37.0, 32.7, 31.8, 31.1, 28.5, 28.3, 28.0, 27.2, 26.4, 26.4, 23.3, 18.6, 17.4, 16.3, 15.5.

Methyl- d_3


(3*R*,5*R*)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1*H*-pyrrol-1-yl)-3,5-dihydroxyheptanoate (**10b**)



Following the general procedure A, the reaction of **10a** (111.7 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **10b** (50.9

mg, 44%, 99% D) as a white solid: ^1H NMR (500 MHz, CDCl_3) δ 7.22 - 7.13 (m, 9 H), 7.06 (d, $J = 8.0$ Hz, 2 H), 7.03 - 6.96 (m, 3 H), 6.86 (s, 1 H), 4.24 - 4.04 (m, 2 H), 4.04 - 3.88 (m, 1 H), 3.82 - 3.71 (m, 1 H), 3.70 - 3.48 (m, 3 H), 2.41 (d, $J = 6.1$ Hz, 2 H), 1.74 - 1.58 (m, 3 H), 1.54 (d, $J = 7.1$ Hz, 6 H). ^{13}C NMR (126 MHz, CDCl_3) δ 173.0, 164.8, 162.2 (d, $J = 247.5$ Hz), 141.5, 138.3, 134.6, 133.2 (d, $J = 8.1$ Hz), 130.5, 128.69, 128.65, 128.3, 126.5, 123.5, 121.8, 119.6, 115.4 (d, $J = 21.4$ Hz), 69.6, 68.9, 41.7, 41.2, 41.1, 39.1, 26.1, 21.8, 21.7. ^{19}F NMR (471 MHz, CDCl_3) δ -113.5. ATR-FTIR (cm^{-1}): 3416, 2958, 2924, 2854, 1727, 1657, 1509, 1313, 1156, 909, 733. HRMS (ESI $^+$) Calcd for $\text{C}_{34}\text{H}_{34}\text{D}_3\text{FN}_2\text{O}_5\text{Na}$ $[\text{M}+\text{Na}]^+$: 598.2767, found: 598.2764.

The corresponding non-deuterated product:




Methyl

(3*R*,5*R*)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1*H*-

pyrrol-1-yl)-3,5-dihydroxyheptanoate **10b-H**⁵: ¹H NMR (400 MHz, CDCl₃) δ 7.22 - 7.12 (m, 9 H), 7.06 (d, *J* = 8.0 Hz, 2 H), 7.03 - 6.94 (m, 3 H), 6.87 (s, 1 H), 4.24 - 4.04 (m, 2 H), 4.03 - 3.86 (m, 1 H), 3.80 - 3.65 (m, 5 H), 3.62 - 3.51 (m, 2 H), 2.41 (d, *J* = 6.1 Hz, 2 H), 1.72 - 1.61 (m, 3 H), 1.54 (d, *J* = 7.1 Hz, 6 H). ¹³C NMR (101 MHz, CDCl₃) δ 173.0, 164.8, 162.2 (d, *J* = 247.6 Hz), 141.5, 138.3, 134.6, 133.2 (d, *J* = 8.1 Hz), 130.4, 128.7, 128.6, 128.3, 126.5, 123.5, 121.8, 119.6, 115.4 (d, *J* = 21.4 Hz), 69.6, 68.9, 51.9, 41.7, 41.2, 41.1, 39.0, 26.1, 21.8, 21.7. ¹⁹F NMR (376 MHz, CDCl₃) δ -113.5.


Methyl-*d*₃

(1*S*,2*S*,4*aR*,7*S*,9*aS*,10*S*,10*aR*)-2,7-dihydroxy-1-methyl-8-methylene-13-oxo-1,2,4b,5,6,7,8,9,10,10*a*-decahydro-4*a*,1-(epoxymethano)-7,9*a*-methanobenzo[*a*]azulene-10-carboxylate (**11b**)



Following the general procedure A, the reaction of **11a** (69.2 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K₂CO₃ (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **11b** (64.3 mg, 89%, 99% D) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 6.32 (dd, *J* = 9.3, 0.9 Hz, 1 H), 5.91 (dd, *J* = 9.3, 3.7 Hz, 1 H), 5.28 (dd, *J* = 3.1, 1.9 Hz, 1 H), 4.97 (d, *J* = 2.2 Hz, 1 H), 4.16 (dd, *J* = 7.3, 3.7 Hz, 1 H), 3.21 (d, *J* = 10.7 Hz, 1 H), 2.79 (d, *J* = 10.7 Hz, 1 H), 2.26 - 2.12 (m, 2 H), 2.12 - 2.01 (m, 2 H), 2.00 - 1.88 (m, 3 H), 1.88 - 1.79 (m, 1 H), 1.79 - 1.70 (m, 1 H), 1.72 - 1.63 (m, 2 H), 1.25 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ 156.9, 133.0, 132.3, 107.6, 78.2, 69.8, 53.4, 52.8, 51.1, 50.6, 50.5, 44.8, 43.1, 38.2, 17.0, 14.4. ATR-FTIR (cm⁻¹): 3375, 2941, 1764, 1748, 1267, 753. EI-MS (*m/z*, relative intensity): 301 (M⁺-COOCD₃, 16), 239 (34), 238 (100), 223 (24), 209 (27), 195 (27), 193 (23), 181 (20), 180 (22), 165 (37), 155 (42), 152 (26), 141 (24), 128 (22), 115 (21). HRMS (ESI⁺) Calcd for C₂₀H₂₁D₃O₆Na [M+Na]⁺: 386.1653, found: 386.1651.

The corresponding non-deuterated product:




Methyl
(1*S*,2*S*,4*aR*,7*S*,9*aS*,10*S*,10*aR*)-2,7-dihydroxy-1-methyl-8-methyl-13-oxo-1,2,4*b*,5,6,7,8,9,10,10*a*-decahydro-4*a*,1-(epoxymethano)-7,9*a*-methanobenzo[*a*]azulene-10-carboxylate

11b-H (CAS: 510-50-9): $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 6.32

(dd, $J = 9.3, 0.9$ Hz, 1 H), 5.91 (dd, $J = 9.3, 3.7$ Hz, 1 H), 5.28 (dd, $J = 3.0, 1.9$ Hz, 1 H), 4.97 (d, $J = 2.1$ Hz, 1 H), 4.16 (dd, $J = 7.1, 3.7$ Hz, 1 H), 3.74 (s, 3 H), 3.21 (d, $J = 10.7$ Hz, 1 H), 2.79 (d, $J = 10.7$ Hz, 1 H), 2.26 - 2.12 (m, 2 H), 2.12 - 2.01 (m, 2 H), 2.00 - 1.87 (m, 3 H), 1.86 - 1.78 (m, 1 H), 1.80 - 1.70 (m, 1 H), 1.72 - 1.62 (m, 2 H), 1.25 (s, 3 H). $^{13}\text{C NMR}$ (101 MHz, CDCl_3) δ 178.3, 172.5, 156.9, 133.0, 132.3, 107.6, 90.4, 78.2, 69.8, 53.4, 52.8, 52.2, 51.1, 50.6, 50.5, 44.8, 43.1, 38.2, 17.0, 14.4.

Methyl- d_3 (3*R*,4*S*,5*R*)-3,4,5-trihydroxycyclohex-1-ene-1-carboxylate (**12b**)




Following the general procedure A, the reaction of **12a** (34.8 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **12b** (35.2 mg, 92%,

99% D) as a white solid: $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 6.64 - 6.59 (m, 1 H), 4.97 - 4.80 (m, 2 H), 4.67 (d, $J = 4.2$ Hz, 1 H), 4.28 - 4.16 (m, 1 H), 3.92 - 3.79 (m, 1 H), 3.62 - 3.51 (m, 1 H), 2.47 - 2.36 (m, 1 H), 2.11 - 1.99 (m, 1 H). $^{13}\text{C NMR}$ (101 MHz, $\text{DMSO-}d_6$) δ 166.8, 139.9, 127.4, 70.0, 66.9, 65.5, 29.6. ATR-FTIR (cm^{-1}): 3430, 1653, 1255, 1027, 825, 764, 626. HRMS (ESI $^+$) Calcd for $\text{C}_8\text{H}_9\text{D}_3\text{O}_5\text{Na}$ $[\text{M}+\text{Na}]^+$: 214.0765, found: 214.0763.

The gram scale reaction of **12b**:

The reaction of **12a** (0.8700 g, 5.0 mmol, 1.0 equiv), **DMTT** (1.7400 g, 5.0 mmol, 1.0 equiv), K_2CO_3 (1.3800 g, 10.0 mmol, 2.0 equiv), and MeCN (50 mL) at room temperature for 12 h afford **12b** (0.8734 g, 91%, 99% D) as a white solid.

The corresponding non-deuterated product:




Methyl

(3*R*,4*S*,5*R*)-3,4,5-trihydroxycyclohex-1-ene-1-carboxylate

12b-H (CAS: 40983-58-2): ^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 6.64 - 6.58 (m, 1 H), 4.94 - 4.81 (m, 2 H), 4.67 (s, 1 H), 4.21 (s, 1 H), 3.92 - 3.78 (m, 1 H), 3.66 (s, 3 H), 3.63 - 3.52 (m, 1 H), 2.48 - 2.36 (m, 1 H), 2.11 - 1.99 (m, 1 H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ 166.8, 139.9, 127.4, 70.0, 66.9, 65.5, 51.7, 29.7.

Methyl- d_3


5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanoate (**13b**)



Following the general procedure A, the reaction of **13a** (48.9 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **13b** (33.8 mg, 65%, 99% D) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 6.01 (s, 1 H), 5.81 (s, 1 H),

4.60 - 4.44 (m, 1 H), 4.41 - 4.28 (m, 1 H), 3.24 - 3.06 (m, 1 H), 2.89 (dd, $J = 12.9, 4.9$ Hz, 1 H), 2.75 (d, $J = 13.1$ Hz, 1 H), 2.32 (t, $J = 7.4$ Hz, 2 H), 1.82 - 1.54 (m, 4 H), 1.52 - 1.33 (m, 2 H). ^{13}C NMR (101 MHz, CDCl_3) δ 174.2, 164.2, 62.1, 60.3, 55.6, 40.5, 33.6, 28.4, 28.2, 24.7. ATR-FTIR (cm^{-1}): 3440, 1676, 1515, 1465, 997, 750. HRMS (ESI^+) Calcd for $\text{C}_{11}\text{H}_{15}\text{D}_3\text{N}_2\text{O}_3\text{SNa}$ [$\text{M}+\text{Na}$] $^+$: 284.1119, found: 284.1120.

The corresponding non-deuterated product:




Methyl

5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanoate **13b-H** (CAS: 608-16-2): ^1H NMR (400 MHz, CDCl_3) δ 5.99 (s, 1 H), 5.70 (s, 1 H), 4.62 - 4.42 (m, 1 H), 4.41 - 4.24 (m, 1 H), 3.65 (s, 3 H), 3.25 -

3.06 (m, 1 H), 2.89 (dd, $J = 12.9, 4.9$ Hz, 1 H), 2.74 (d, $J = 12.8$ Hz, 1 H), 2.32 (t, $J = 7.5$ Hz, 2 H), 1.83 - 1.53 (m, 4 H), 1.54 - 1.33 (m, 2 H). ^{13}C NMR (101 MHz, CDCl_3) δ 174.1, 164.0, 62.0, 60.2, 55.5, 51.5, 40.5, 33.6, 28.4, 28.2, 24.7.

Methyl- d_3 (tert-butoxycarbonyl)glycylglycinate (**14b**)




Following the general procedure A, the reaction of **14a** (46.5 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **14b** (41.2 mg, 83%, 99% D) as a colorless oil: ^1H NMR (500 MHz, CDCl_3) δ 6.97 (t, $J = 5.5$ Hz, 1 H), 5.45 (s, 1 H), 4.02 (d, $J = 5.4$ Hz, 2 H), 3.83 (d, $J = 5.9$ Hz, 2 H), 1.42 (s, 9 H). ^{13}C NMR (126 MHz, CDCl_3) δ 170.2, 170.0, 156.1, 80.2, 44.0, 41.0, 28.2. ATR-FTIR (cm^{-1}): 3326, 2979, 2935, 1749, 1663, 1522, 1368, 1171, 1032, 945, 743. HRMS (ESI $^+$) Calcd for $\text{C}_{10}\text{H}_{15}\text{D}_3\text{N}_2\text{O}_5\text{Na}$ $[\text{M}+\text{Na}]^+$: 272.1296, found: 272.1296.

The gram scale reaction of **14b**:


The reaction of **14a** (1.230 g, 5.3 mmol, 1.0 equiv), **DMTT** (1.844 g, 5.3 mmol, 1.0 equiv), K_2CO_3 (1.463 g, 10.6 mmol, 2.0 equiv), and MeCN (53 mL) at room temperature for 12 h afford **14b** (1.2141 g, 92%, 99% D) as a white solid.

The corresponding non-deuterated product:




Methyl (tert-butoxycarbonyl)glycylglycinate **14b-H** (CAS: 53487-98-2): ^1H NMR (400 MHz, CDCl_3) δ 6.95 (t, $J = 6.9$ Hz, 1 H), 5.43 (s, 1 H), 4.03 (d, $J = 5.3$ Hz, 2 H), 3.83 (d, $J = 5.9$ Hz, 2 H), 3.72 (d, $J = 1.1$ Hz, 3 H), 1.42 (d, $J = 1.0$ Hz, 9 H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.2, 170.0, 156.1, 80.3, 52.3, 44.0, 41.0, 28.2.

General Procedure B:




To a Schlenk tube was added carboxylic acid **a** (0.2 mmol, 1.0 equiv), **DMTT** (0.2 mmol, 2.0 equiv), KOH (22.4 mg, 0.4 mmol, 2.0 equiv), H₂O (1 mL), and MeCN (1 mL). The reaction was stirring at room temperature for 12 h. The resulting mixture was concentrated in vacuo and the residue was purified by column chromatography to afford the corresponding product **b**.

Methyl-*d*₃ (((9*H*-fluoren-9-yl)methoxy)carbonyl)glycylglycylglycinate (**15b**)



Following the general procedure B, the reaction of **15a** (82.2 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), KOH (22.4 mg, 0.4 mmol, 2.0 equiv), H₂O (1 mL), and MeCN (1 mL) at room temperature for 12 h afford **15b** (39.8 mg, 46%, 99% D) as a white solid: ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.30 (t, *J* = 5.9 Hz, 1 H), 8.17 (t, *J* = 5.9 Hz, 1 H), 7.89 (d, *J* = 7.5 Hz, 2 H), 7.73 (s, 1 H), 7.58 (t, *J* = 6.1 Hz, 1 H), 7.42 (t, *J* = 7.4 Hz, 2 H), 7.36 - 7.31 (m, 2 H), 4.29 (d, *J* = 7.5 Hz, 1 H), 4.25 - 4.20 (m, 1 H), 3.85 (d, *J* = 5.8 Hz, 2 H), 3.76 (d, *J* = 5.8 Hz, 2 H), 3.67 (d, *J* = 6.0 Hz, 2 H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 170.2, 169.5, 169.4, 156.5, 143.9, 140.7, 127.7, 127.1, 125.3, 120.1, 65.8, 46.7, 43.5, 41.7, 40.5. ATR-FTIR (cm⁻¹): 3429, 1655, 1002, 825, 764, 627. EI-MS (*m/z*, relative intensity): 207 (93), 206 (90), 205 (59), 194 (28), 193 (45), 192 (45), 191 (40), 190 (25), 179 (22), 178 (70), 177 (100), 176 (60), 175 (30), 133 (20), 89 (22), 57 (28). HRMS (ESI⁺) Calcd for C₂₂H₂₀D₃N₃O₆Na [M+Na]⁺: 451.1667, found: 451.1676.

The corresponding non-deuterated product:




Methyl

(((9H-fluoren-9-yl)methoxy)carbonyl)glycylglycylglycinate **15b-H**⁶: ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.30 (t, *J* = 6.0 Hz, 1 H), 8.16 (t, *J* = 5.9 Hz, 1 H), 7.89 (d, *J* =

7.5 Hz, 2 H), 7.72 (d, *J* = 7.4 Hz, 1 H), 7.57 (t, *J* = 6.1 Hz, 1 H), 7.42 (td, *J* = 7.4, 1.1 Hz, 2 H), 7.33 (td, *J* = 7.4, 1.2 Hz, 2 H), 4.29 (d, *J* = 7.4 Hz, 1 H), 4.27 - 4.18 (m, 1 H), 3.85 (d, *J* = 5.9 Hz, 2 H), 3.75 (d, *J* = 5.8 Hz, 2 H), 3.66 (d, *J* = 6.0 Hz, 2 H), 3.62 (s, 3 H). ¹³C NMR (101 MHz, DMSO-*d*₆) δ 170.2, 169.5, 169.4, 156.5, 143.9, 140.7, 127.7, 127.1, 125.3, 120.1, 65.8, 51.7, 46.6, 43.5, 41.7, 40.5.


2-(4-(Methoxy-*d*₃)phenyl)ethan-1-ol (**16b**)



Following the general procedure A, the reaction of **16a** (27.6 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K₂CO₃ (55.2 mg, 0.4 mmol, 2.0 equiv),

and MeCN (2 mL) at room temperature for 12 h afford **16b** (26.6 mg, 86%, 99% D) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 7.14 (d, *J* = 8.5 Hz, 2 H), 6.86 (d, *J* = 8.5 Hz, 2 H), 3.90 - 3.64 (m, 2 H), 2.80 (t, *J* = 6.6 Hz, 2 H), 1.64 (bs, 1 H). ¹³C NMR (101 MHz, CDCl₃) δ 158.2, 130.4, 129.9, 114.0, 63.8, 38.2. ATR-FTIR (cm⁻¹): 3401, 1711, 1615, 1516, 1448, 1370, 1219, 1088, 828. HRMS (ESI⁺) Calcd for C₉H₉D₃O₂Na [M+Na]⁺: 178.0918, found: 178.0916.


The corresponding non-deuterated product:



2-(4-Methoxyphenyl)ethan-1-ol **16b-H** (CAS: 702-23-8):


¹H NMR (500 MHz, CDCl₃) δ 7.15 (d, *J* = 8.6 Hz, 2 H), 6.86 (d, *J* = 8.6 Hz, 2 H), 3.85 - 3.80 (m, 2 H), 3.79 (s, 3 H), 2.81 (t, *J* = 6.5 Hz, 2 H), 1.43 (bs, 1 H). ¹³C NMR (126 MHz, CDCl₃) δ 158.2, 130.4, 130.0, 114.0, 63.8, 55.3, 38.2.

6-(Methoxy-*d*₃)-1H-indole (**17b**)




Following the general procedure A, the reaction of **17a** (26.6 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **17b** (27.6 mg, 92%, 99% D) as a colorless oil: 1H NMR (400 MHz, $CDCl_3$) δ 8.01 (s, 1 H), 7.54 (d, $J = 8.5$ Hz, 1 H), 7.15 - 7.05 (m, 1 H), 6.89 - 6.80 (m, 2 H), 6.52 - 6.49 (m, 1 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 156.3, 136.5, 123.0, 122.1, 121.2, 109.8, 102.4, 94.5. ATR-FTIR (cm^{-1}): 3395, 2955, 2909, 2835, 1627, 1502, 1458, 1161, 1025, 811, 717. HRMS (ESI⁺) Calcd for $C_9H_7D_3NO$ $[M+H]^+$: 151.0945, found: 151.0945.

The corresponding non-deuterated product:




6-(Methoxy- d_3)-1H-indole **17b-H** (CAS: 3189-13-7): 1H NMR (400 MHz, $CDCl_3$) δ 8.01 (s, 1 H), 7.55 (d, $J = 8.5$ Hz, 1 H), 7.12 - 7.04 (m, 1 H), 6.92 - 6.79 (m, 2 H), 6.57 - 6.42 (m, 1 H), 3.86 (s, 3 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 156.3, 136.5, 123.0, 122.1, 121.2, 109.8, 102.3, 94.5, 55.6.

4-(Methoxy- d_3)-*N*-phenylaniline (**18b**)



Following the general procedure A, the reaction of **18a** (37.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **18b** (24.2 mg, 60%, 99% D) as a white solid: 1H NMR (400 MHz, $CDCl_3$) δ 7.28 - 7.18 (m, 2 H), 7.14 - 7.04 (m, 2 H), 6.99 - 6.77 (m, 5 H), 5.50 (s, 1 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 155.2, 145.1, 135.7, 129.3, 122.2, 119.5, 115.6, 114.6. ATR-FTIR (cm^{-1}): 3395, 3057, 3032, 2962, 2928, 2834, 1598, 1515, 1247, 1031, 829, 744. HRMS (ESI⁺) Calcd for $C_{13}H_{10}D_3NONa$ $[M+Na]^+$: 225.1078, found: 225.1080.

The corresponding non-deuterated product:




4-(Methoxy-*d*₃)-*N*-phenylaniline **18b-H** (CAS: 1208-86-2):

¹H NMR (400 MHz, CDCl₃) δ 7.26 - 7.20 (m, 2 H), 7.12 - 7.07 (m, 2 H), 6.96 - 6.81 (m, 5 H), 5.51 (s, 1 H), 3.82 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ 155.2, 145.1, 135.7,

129.3, 122.2, 119.5, 115.6, 114.6, 55.5.


N-(4-(Methoxy-*d*₃)phenyl)acetamide (**19b**)



Following the general procedure A, the reaction of **19a** (30.2 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K₂CO₃ (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **19b** (32.9 mg, 98%,

99% D) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 7.99 (s, 1 H), 7.37 (d, *J* = 9.0 Hz, 2 H), 6.80 (d, *J* = 8.9 Hz, 2 H), 2.09 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ 168.7, 156.3, 131.0, 122.0, 114.0, 24.1. ATR-FTIR (cm⁻¹): 3244, 3070, 2961, 1651, 1603, 1515, 1318, 1113, 1029, 818, 773. HRMS (ESI⁺) Calcd for C₉H₈D₃NO₂Na [M+Na]⁺: 191.0871, found: 191.0868.

The corresponding non-deuterated product:




N-(4-(Methoxy-*d*₃)phenyl)acetamide **19b-H** (CAS: 51-66-1):

¹H NMR (400 MHz, CDCl₃) δ 7.93 (s, 1 H), 7.37 (d, *J* = 9.0 Hz, 2 H), 6.81 (d, *J* = 9.0 Hz, 2 H), 3.75 (s, 3 H), 2.10 (s, 3 H).

¹³C NMR (101 MHz, CDCl₃) δ 168.7, 156.3, 131.0, 122.0,

114.0, 55.4, 24.1.

(3*R*,4*S*)-1-(4-Fluorophenyl)-3-((*S*)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-(methoxy-*d*₃)phenyl)azetididin-2-one (**20b**)




Following the general procedure A, the reaction of **20a** (81.9 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K₂CO₃ (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at

room temperature for 12 h afford **20b** (83.9 mg, 98%, 99% D) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 7.38 - 7.20 (m, 6 H), 7.06 - 6.99 (m, 2 H), 6.98 - 6.87 (m, 4 H), 4.72 (t, $J = 5.9$ Hz, 1 H), 4.61 (d, $J = 2.3$ Hz, 1 H), 3.17 - 2.95 (m, 2 H), 2.06 - 1.85 (m, 4 H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.7, 162.0 (d, $J = 245.3$ Hz), 159.7, 158.9 (d, $J = 243.4$ Hz), 140.1 (d, $J = 3.1$ Hz), 133.7 (d, $J = 2.7$ Hz), 129.2, 127.3 (d, $J = 8.0$ Hz), 127.1, 118.4, 118.3 (d, $J = 7.7$ Hz), 115.7 (d, $J = 22.7$ Hz), 115.2 (d, $J = 21.3$ Hz), 114.5, 72.9, 61.0, 60.1, 36.5, 24.9. ^{19}F NMR (376 MHz, CDCl_3) δ -115.0, -118.0. ATR-FTIR (cm^{-1}): 3650, 3623, 3504, 2917, 2847, 1741, 1511, 1251, 1223, 750. HRMS (ESI $^+$) Calcd for $\text{C}_{25}\text{H}_{20}\text{D}_3\text{F}_2\text{NO}_3\text{Na}$ $[\text{M}+\text{Na}]^+$: 449.1727, found: 449.1723.

The gram scale reaction of **20b**:

The reaction of **20a** (1.085 g, 2.65 mmol, 1.0 equiv), **DMTT** (0.922 g, 2.65 mmol, 1.0 equiv), K_2CO_3 (0.731 g, 5.3 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **20b** (1.0737 g, 95%, 99% D) as a white solid.


The corresponding non-deuterated product:



(3*R*,4*S*)-1-(4-Fluorophenyl)-3-((*S*)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-methoxyphenyl)azetidin-2-one **20b-H**: ^1H NMR (400 MHz, CDCl_3) δ 7.36 - 7.20 (m, 6 H), 7.09 - 6.98 (m, 2 H), 6.99 - 6.86 (m, 4 H), 4.72 (t, $J = 5.9$ Hz, 1 H), 4.61 (d, $J = 2.4$ Hz, 1 H), 3.83 (s, 3 H), 3.14

- 3.05 (m, 1 H), 2.85 (s, 1 H), 2.07 - 1.84 (m, 4 H). ^{13}C NMR (101 MHz, CDCl_3) δ 167.7, 162.0 (d, $J = 245.5$ Hz), 159.7, 158.9 (d, $J = 243.2$ Hz), 140.1 (d, $J = 3.1$ Hz), 133.7 (d, $J = 2.7$ Hz), 129.2, 127.3 (d, $J = 7.9$ Hz), 127.1, 118.4, 118.3 (d, $J = 7.8$ Hz), 115.7 (d, $J = 22.7$ Hz), 115.2 (d, $J = 21.3$ Hz), 114.6, 72.9, 61.0, 60.2, 55.2, 36.5, 24.9. ^{19}F NMR (376 MHz, CDCl_3) δ -115.0, -118.1.

(8*R*,9*S*,13*S*,14*S*,17*R*)-17-Ethynyl-3-(methoxy-*d*₃)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[*a*]phenanthren-17-ol (**21b**)




21b

Following the general procedure A, the reaction of **21a** (59.3 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **21b** (61.6 mg, 98%, 99% D) as a white solid: 1H NMR (400 MHz, $CDCl_3$) δ 7.23 (d, $J = 8.6$ Hz, 1 H), 6.73 (dd, $J = 8.6, 2.8$ Hz, 1 H), 6.65 (d, $J = 2.7$ Hz, 1 H), 2.91 - 2.83 (m, 2 H), 2.62 (s, 1 H), 2.44 - 2.31 (m, 2 H), 2.28 - 2.20 (m, 1 H), 2.12 (s, 1 H), 2.10 - 2.00 (m, 1 H), 1.99 - 1.86 (m, 2 H), 1.84 - 1.67 (m, 3 H), 1.59 - 1.32 (m, 4 H), 0.90 (s, 3 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 157.3, 137.9, 132.5, 126.3, 113.7, 111.4, 87.5, 79.8, 74.0, 49.4, 47.1, 43.5, 39.4, 38.9, 32.7, 29.8, 27.2, 26.3, 22.8, 12.7. ATR-FTIR (cm^{-1}): 3284, 2904, 2868, 1611, 1501, 1448, 1287, 1251, 1139, 1060, 906, 735. HRMS (ESI⁺) Calcd for $C_{21}H_{24}D_3O_2$ $[M+H]^+$: 314.2194, found: 314.2193.

The gram scale reaction of **21b**:

The reaction of **21a** (1.097 g, 3.7 mmol, 1.0 equiv), **DMTT** (1.288 g, 3.7 mmol, 1.0 equiv), K_2CO_3 (1.021 g, 7.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **21b** (1.1133 g, 96%, 99% D) as a white solid.


The corresponding non-deuterated product:



21b-H


(8*R*,9*S*,13*S*,14*S*,17*R*)-17-Ethynyl-3-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6*H*-cyclopenta[*a*]phenanthren-17-ol **21b-H** (CAS: 72-33-3): 1H NMR (400 MHz, $CDCl_3$) δ 7.23 (d, $J = 8.7$ Hz, 1 H), 6.73 (dd, $J = 8.6, 2.8$ Hz, 1 H), 6.64 (d, $J = 2.7$ Hz, 1 H), 3.79 (s, 3 H), 2.93 - 2.79 (m, 2 H), 2.62 (s, 1 H), 2.44 - 2.30 (m, 2 H), 2.28 - 2.17 (m, 1 H), 2.07 - 1.97 (m, 2 H), 1.98 - 1.86 (m, 2 H), 1.84 - 1.69 (m, 3 H), 1.60 - 1.30 (m, 4 H), 0.90 (s, 3 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 157.4, 137.9, 132.5, 126.3, 113.8, 111.4, 87.5, 79.8, 74.0, 55.2, 49.4, 47.1, 43.5, 39.4, 38.9, 32.7, 29.8, 27.2, 26.4, 22.8, 12.7.

(R)-5-((*S*)-1,2-Dihydroxyethyl)-3,4-bis(methoxy-*d*₃)furan-2(*5H*)-one (**22b**)




Following the general procedure A, the reaction of **22a** (35.2 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), K_2CO_3 (110.4 mg, 0.8 mmol, 4.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **22b** (38.4 mg, 91%, 99% D) as a colorless oil: 1H NMR (400 MHz, $CDCl_3$) δ 4.67 (d, $J = 2.9$ Hz, 1 H), 3.97 - 3.88 (m, 1 H), 3.88 - 3.75 (m, 2 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 75.8, 69.9, 63.3. ATR-FTIR (cm^{-1}): 3743, 3476, 3417, 1752, 1677, 1515, 1068, 746. HRMS (ESI⁺) Calcd for $C_8H_6D_6O_6Na$ [$M+Na$]⁺: 233.0903, found: 233.0903.

The corresponding non-deuterated product:




(R)-5-((*S*)-1,2-Dihydroxyethyl)-3,4-bis(methoxy)furan-2(*5H*)-one **22b-H**⁹: 1H NMR (400 MHz, $CDCl_3$) δ 4.67 (d, $J = 2.7$ Hz, 1 H), 4.16 (s, 3 H), 3.97 - 3.89 (m, 1 H), 3.88 - 3.72 (m, 2 H), 3.83 (s, 3 H), 3.03 (s, 1 H), 2.67 (s, 1 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 169.6, 157.8, 122.9, 75.8, 69.9, 63.3, 60.5, 59.5.

(5-(Methoxy-*d*₃)-6-methylpyridine-3,4-diyl)dimethanol (**23b**)



Following the general procedure A, the reaction of **23a** (33.8 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **23b** (30.8 mg, 83%, 99% D) as a colorless oil: 1H NMR (400 MHz, $DMSO-d_6$) δ 7.38 (s, 1 H), 4.58 (s, 2 H), 4.40 (s, 2 H), 3.16 (s, 2 H), 2.36 (s, 3 H). ^{13}C NMR (101 MHz, $DMSO-d_6$) δ 166.1, 142.2, 137.0, 134.8, 121.6, 58.7, 58.1, 12.0. ATR-FTIR (cm^{-1}): 3425, 1653, 1026, 825, 764, 629. HRMS (ESI⁺) Calcd for $C_9H_{11}D_3NO_3$ [$M+H$]⁺: 187.1156, found: 187.1158.

The corresponding non-deuterated product:



(5-Methoxy-6-methylpyridine-3,4-diyl)dimethanol **23b-H**¹⁰:

1H NMR (400 MHz, $DMSO-d_6$) δ 7.37 (s, 1 H), 4.59 (s, 2 H),


4.40 (s, 2 H), 3.97 (s, 3 H), 2.37 (s, 3 H). ^{13}C NMR (101 MHz, $\text{DMSO-}d_6$) δ 166.2, 142.0, 136.8, 134.6, 121.3, 58.9, 58.0, 45.0, 11.9.

2-((Methyl- d_3)thio)aniline (**24b**)




Following the general procedure A, the reaction of 2-aminobenzenethiol **24a** (25.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (**24b**) (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **24b** (19.3 mg, 68%, 99% D) as a colorless oil: ^1H NMR (400 MHz, CDCl_3) δ 7.36 (dd, $J = 7.9, 1.5$ Hz, 1 H), 7.10 (td, $J = 7.7, 1.5$ Hz, 1 H), 6.80 - 6.65 (m, 2 H), 4.27 (bs, 2 H). ^{13}C NMR (101 MHz, CDCl_3) δ 147.0, 133.4, 128.8, 120.1, 118.7, 114.8. ATR-FTIR (cm^{-1}): 3421, 3346, 3057, 3016, 1653, 1607, 1465, 1437, 1300, 914, 744. HRMS (ESI $^+$) Calcd for $\text{C}_7\text{H}_7\text{D}_3\text{NS}$ $[\text{M}+\text{H}]^+$: 143.0717, found: 143.0715.

The corresponding non-deuterated product:




2-(Methylthio)aniline **24b-H** (CAS: 2987-53-3): ^1H NMR (400 MHz, CDCl_3) δ 7.36 (dd, $J = 7.9, 1.5$ Hz, 1 H), 7.15 - 7.04 (m, 1 H), 6.77 - 6.67 (m, 2 H), 4.27 (s, 2 H), 2.36 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 147.0, 133.4, 128.9, 120.2, 118.7, 114.8, 17.7.

DL-1,4-bis((methyl- d_3)thio)butane-2,3-diol (**25b**)




Following the general procedure A, the reaction of DL-1,4-dithiothreitol **25a** (30.8 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), K_2CO_3 (110.4 mg, 0.8 mmol, 4.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **25b** (28.8, 76%, 99% D) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 3.77 - 3.69 (m, 2 H), 2.83 - 2.78 (m, 2 H), 2.77 - 2.64 (m, 4 H). ^{13}C NMR (101 MHz, CDCl_3) δ 70.0, 38.1. ATR-FTIR (cm^{-1}): 3235, 2915, 1695, 1429, 1320, 1034, 967, 876, 706. HRMS (ESI $^+$) Calcd for $\text{C}_6\text{H}_8\text{D}_6\text{O}_2\text{S}_2\text{Na}$ $[\text{M}+\text{Na}]^+$: 211.0704, found: 211.0702.

The corresponding non-deuterated product:




DL-1,4-bis((methylthio)butane-2,3-diol) **25b-H**: ^1H NMR (400 MHz, CDCl_3) δ 3.79 - 3.68 (m, 2 H), 2.91 - 2.77 (m, 2 H), 2.76 - 2.67 (m, 4 H), 2.13 (s, 6 H). ^{13}C NMR (101 MHz, CDCl_3) δ 70.0, 38.2, 15.6.

4-Amino-*N*-(methyl- d_3)-*N*-(5-methylisoxazol-3-yl)benzenesulfonamide (**26b**)




Following the general procedure A, the reaction of sulfamethoxazole **26a** (50.7 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **26b** (51.2 mg, 95%, 99% D) as a white solid: ^1H NMR (400 MHz, CDCl_3) δ 7.49 - 7.40 (m, 2 H), 6.61 - 6.56 (m, 2 H), 6.45 (d, $J = 0.9$ Hz, 1 H), 4.28 (s, 2 H), 2.34 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.1, 160.9, 151.4, 129.2, 124.2, 113.9, 97.5, 12.6. ATR-FTIR (cm^{-1}): 3480, 3385, 3236, 2936, 1597, 1446, 1350, 1162, 1003, 917, 834, 692. HRMS (ESI $^+$) Calcd for $\text{C}_{11}\text{H}_{10}\text{D}_3\text{N}_3\text{O}_3\text{S}$ [M] $^+$: 270.0866, found: 270.0867.

The corresponding non-deuterated product:



4-Amino-*N*-methyl-*N*-(5-methylisoxazol-3-yl)benzenesulfonamide **26b-H** 12 : ^1H NMR (400 MHz, CDCl_3) δ 7.53 - 7.39 (m, 2 H), 6.65 - 6.54 (m, 2 H), 6.46 (d, $J = 0.9$ Hz, 1 H), 4.27 (s, 2 H), 3.20 (s, 3 H), 2.35 (d, $J = 0.9$ Hz, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 170.1, 161.0, 151.4, 129.3, 124.3, 113.9, 97.5, 34.8, 12.6.


4-Amino-*N*-(4,6-dimethylpyrimidin-2-yl)-*N*-(methyl- d_3)benzenesulfonamide (**27b**)



Following the general procedure A, the reaction of sulfamethazine **27a** (55.7 mg, 0.2 mmol, 1.0 equiv),


DMTT (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **27b** (36.6 mg, 62%, 99% D) as a white solid: 1H NMR (400 MHz, $CDCl_3$) δ 7.55 (d, $J = 8.8$ Hz, 2 H), 7.32 (s, 1 H), 6.62 (d, $J = 8.7$ Hz, 2 H), 4.17 (s, 2 H), 2.53 (s, 3 H), 2.43 (s, 3 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 166.8, 159.7, 151.2, 129.5, 126.3, 113.9, 107.3, 25.8, 24.3. ATR-FTIR (cm^{-1}): 3474, 3383, 3213, 1581, 1359, 1152, 930, 681. HRMS (ESI⁺) Calcd for $C_{13}H_{13}D_3N_4O_2SNa$ [$M+Na$]⁺: 318.1074, found: 318.1079.

The corresponding non-deuterated product:



4-Amino-*N*-(4,6-dimethylpyrimidin-2-yl)-*N*-methylbenzenesulfonamide **27b-H**^{12b}: 1H NMR (400 MHz, $CDCl_3$) δ 7.53 (d, $J = 8.7$ Hz, 2 H), 7.31 (s, 1 H), 6.61 (d, $J = 8.7$ Hz, 2 H), 4.21 (s, 2 H), 3.38 (s, 3 H), 2.52 (s, 3 H), 2.42 (s, 3 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 166.8, 159.6, 151.1, 129.5, 126.1, 113.8, 107.3, 34.0, 25.8, 24.3.


5-Chloro-*N*-(4-(*N*-(cyclohexylcarbamoyl)-*N*-(methyl-*d*₃)sulfamoyl)phenethyl)-2-methoxybenzamide (**28b**)



Following the general procedure A, the reaction of glibenclamide **28a** (98.8 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K_2CO_3 (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **28b** (62.2 mg, 61%, 99% D) as a white solid: 1H NMR (400 MHz, $CDCl_3$) δ 8.14 (d, $J = 2.8$ Hz, 1 H), 7.81 (t, $J = 5.8$ Hz, 1 H), 7.75 (d, $J = 8.3$ Hz, 2 H), 7.41 (d, $J = 8.3$ Hz, 2 H), 7.36 (dd, $J = 8.8, 2.8$ Hz, 1 H), 7.19 (d, $J = 7.8$ Hz, 1 H), 6.86 (d, $J = 8.8$ Hz, 1 H), 3.77 (s, 3 H), 3.72 (q, $J = 6.7$ Hz, 2 H), 3.66 - 3.54 (m, 1 H), 3.01 (t, $J = 6.9$ Hz, 2 H), 1.91 - 1.81 (m, 3 H), 1.74 - 1.64 (m, 2 H), 1.63 - 1.53 (m, 1 H), 1.37 - 1.25 (m, 2 H), 1.25 - 1.18 (m, 2 H). ^{13}C NMR (101 MHz, $CDCl_3$) δ 164.0, 155.8, 151.8, 146.0, 136.1, 132.4, 131.8, 129.8, 127.1, 126.7, 122.5,

112.8, 56.2, 49.8, 40.5, 35.5, 32.9, 25.4, 24.5. ATR-FTIR (cm⁻¹): 3394, 2934, 2855, 1700, 1655, 1527, 1352, 1270, 1158, 93, 745. HRMS (ESI⁺) Calcd for C₂₄H₂₇D₃ClN₃O₅S [M]⁺: 510.1783, found: 510.1788.


The corresponding non-deuterated product:



5-Chloro-*N*-(4-(*N*-(cyclohexylcarbamoyl)-*N*-(methylsulfamoyl)phenethyl)-2-methoxybenzamide **28b-H**: ¹H NMR (400 MHz, CDCl₃) δ 8.13 (d, *J* = 2.7 Hz, 1 H), 7.81 (t, *J* = 5.5 Hz, 1 H), 7.75 (d, *J* = 8.3 Hz, 2

H), 7.41 (d, *J* = 8.3 Hz, 2 H), 7.35 (dd, *J* = 8.8, 2.8 Hz, 1 H), 7.19 (d, *J* = 7.8 Hz, 1 H), 6.86 (d, *J* = 8.9 Hz, 1 H), 3.77 (s, 3 H), 3.72 (q, *J* = 6.7 Hz, 2 H), 3.67 - 3.53 (m, 1 H), 3.10 (s, 3 H), 3.00 (t, *J* = 7.0 Hz, 2 H), 1.94 - 1.79 (m, 3 H), 1.76 - 1.63 (m, 2 H), 1.63 - 1.51 (m, 1 H), 1.37 - 1.25 (m, 2 H), 1.25 - 1.15 (m, 2 H). ¹³C NMR (101 MHz, CDCl₃) δ 164.0, 155.8, 151.8, 146.0, 136.0, 132.4, 131.8, 129.8, 127.1, 126.7, 122.5, 112.8, 56.2, 49.8, 40.4, 35.4, 32.9, 32.4, 25.3, 24.5.

1-((2*R*,3*S*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3-(methyl-*d*₃)pyrimidine-2,4(1*H*,3*H*)-dione (**29b**)




Following the general procedure A, the reaction of spongouridine **29a** (48.8 mg, 0.2 mmol, 1.0 equiv), **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K₂CO₃ (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL) at room temperature for 12 h afford **29b** (47.3 mg, 91%, 99% D) as a white solid: ¹H

NMR (400 MHz, CD₃OD) δ 7.85 (d, *J* = 8.1 Hz, 1 H), 6.14 (d, *J* = 4.1 Hz, 1 H), 5.74 (d, *J* = 8.1 Hz, 1 H), 4.24 - 4.13 (m, 1 H), 4.10 - 4.05 (m, 1 H), 3.99 - 3.91 (m, 1 H), 3.87 - 3.74 (m, 2 H). ¹³C NMR (101 MHz, CD₃OD) δ 165.6, 152.6, 142.2, 100.4, 88.7, 86.7, 77.8, 77.1, 62.7. ATR-FTIR (cm⁻¹): 2931, 2496, 2240, 2223, 2073, 1660, 1471, 1121, 989, 808. EI-MS (*m/z*, relative intensity): 131 (25), 130 (61), 129 (55), 128 (36),

127 (30), 71 (44), 70 (100), 69 (69). HRMS (ESI⁺) Calcd for C₁₀H₁₁D₃N₂O₆Na [M+Na]⁺: 284.0932, found: 284.0935.

The corresponding non-deuterated product:




1-((2*R*,3*S*,4*S*,5*R*)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3-(methyl)pyrimidine-2,4(1*H*,3*H*)-dione

29b-H¹³: ¹H NMR (400 MHz, CD₃OD) δ 7.85 (d, *J* = 8.1 Hz, 1 H), 6.14 (d, *J* = 4.1 Hz, 1 H), 5.74 (d, *J* = 8.1 Hz, 1 H), 4.21 - 4.14 (m, 1 H), 4.07 (t, *J* = 3.1 Hz, 1 H), 3.98 - 3.89 (m, 1 H), 3.86 - 3.73 (m, 2 H), 3.29 (s, 3 H). ¹³C NMR (101 MHz, CD₃OD) δ 165.6, 152.6, 142.2, 100.4, 88.7, 86.8, 77.8, 77.1, 62.7, 28.0.

Section S5. The application in synthesis of deuterated pharmaceuticals


Synthesis of *d*₃-bifendatum:



To a 10 mL round flask was added ester **30a** (83.6 mg, 0.2 mmol, 1.0 equiv), NaOH aq. (1 M, 0.8 mmol, 4.0 equiv), and MeCN (2 mL). The mixture was stirring at 60 °C until the starting material was disappeared completely. **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv) was added and the reaction was stirring at room temperature for 12 h. The resulting mixture was concentrated in vacuo and the residue was purified by

column chromatography to afford the corresponding product **30b** (54.0 mg, 64%, 99% D) as a white solid.


Bis(methyl- d_3) 7,7'-dimethoxy-[4,4'-bibenzo[*d*][1,3]dioxole]-5,5'-dicarboxylate (**30b**)



^1H NMR (400 MHz, CD_3OD) δ 7.38 (s, 2 H), 5.99 (s, 4 H), 3.96 (s, 6 H). ^{13}C NMR (101 MHz, CD_3OD) δ 166.3, 147.1, 142.4, 138.1, 123.4, 112.2, 110.9, 102.3, 56.5. ATR-FTIR (cm^{-1}): 2951, 2902, 2844, 1723, 1638, 1592, 1432, 1531, 1319, 1173, 1044, 912, 742. HRMS (ESI $^+$) Calcd for $\text{C}_{20}\text{H}_{12}\text{D}_6\text{O}_{10}\text{Na}$ $[\text{M}+\text{Na}]^+$: 447.1169, found:

447.1165.


The corresponding non-deuterated product:



Bismethyl 7,7'-dimethoxy-[4,4'-bibenzo[*d*][1,3]dioxole]-5,5'-dicarboxylate **30a** (CAS: 73536-69-3): ^1H NMR (400 MHz, CD_3OD) δ 7.37 (s, 2 H), 5.98 (s, 4 H), 3.95 (s, 6 H), 3.66 (s, 6 H). ^{13}C NMR (101 MHz, CD_3OD) δ 166.3, 147.0, 142.3, 138.0, 123.2, 112.1, 110.7, 102.3, 56.4,

51.8.

Synthesis of d_3 -methoxsalen:




To a 25 mL dried Schlenk tube was added **31a** (43.2 mg, 0.2 mmol, 1.0 equiv) and anhydrous CH_2Cl_2 (2 mL). Then BBr_3 in DCM (0.8 mL, 0.8 mmol, 1 M, 4.0

equiv) was dropwise at 0 °C slowly under nitrogen atmosphere. The mixture was warmed to room temperature naturally and stirring for 6 h. After that, 2 mL H₂O was added to quench the reaction. The two liquid layers were separated, and the aqueous layer was extracted with DCM. The combined organic layers were washed with brine and dried with MgSO₄. After filtration and evaporation, the residue was purified by column chromatography to give the corresponding phenol derivatives.

To a Schlenk tube was added the corresponding phenol derivatives, **DMTT** (70.2 mg, 0.2 mmol, 1.0 equiv), K₂CO₃ (55.2 mg, 0.4 mmol, 2.0 equiv), and MeCN (2 mL). The mixture was stirring at room temperature for 12 h. The resulting mixture was concentrated in vacuo and the residue was purified by column chromatography to afford the corresponding product **31b** (36.1 mg, 82%, 99% D) as a white solid.

9-(Methoxy-*d*₃)-7*H*-furo[3,2-*g*]chromen-7-one (**31b**)




31b

¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, *J* = 9.6 Hz, 1 H), 7.65 (d, *J* = 2.2 Hz, 1 H), 7.30 (s, 1 H), 6.78 (d, *J* = 2.2 Hz, 1 H), 6.31 (d, *J* = 9.6 Hz, 1 H). ¹³C NMR (101 MHz, CDCl₃) δ 160.4, 147.4, 146.5, 144.3, 142.7, 132.5, 126.0, 116.3, 114.4, 112.8, 106.6.

ATR-FTIR (cm⁻¹): 3140, 3114, 3067, 1712, 1585, 1442, 1038, 1159, 1107, 872.

HRMS (ESI⁺) Calcd for C₁₂H₅D₃O₄Na [M+Na]⁺: 242.0503, found: 242.0507.

The corresponding non-deuterated product:




31a

9-Methoxy-7*H*-furo[3,2-*g*]chromen-7-one **31a** (CAS: 298-81-7):
¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 9.6 Hz, 1 H), 7.66 (d, *J* = 2.2 Hz, 1 H), 7.32 (s, 1 H), 6.79 (d, *J* = 2.2 Hz, 1 H), 6.33 (d, *J* = 9.6 Hz, 1 H), 4.25 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ

160.4, 147.5, 146.5, 144.3, 142.8, 132.6, 126.0, 116.3, 114.5, 112.9, 106.6, 61.2.


Section S6. The Synthesis of *N,N*-dimethylamines **33**

General Procedure C:




To a Schlenk tube was added amines **32** (0.2 mmol, 1.0 equiv), **DMTT** (0.4 mmol, 2.0 equiv), $\text{Ni(OAc)}_2 \cdot 4\text{H}_2\text{O}$ (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and $\text{DCM/H}_2\text{O}$ (2 mL, v:v = 20/1). The mixture was stirring at room temperature for 12 hours. Then the resulting mixture was concentrated in vacuo and the residue was purified by column chromatography to afford the corresponding product **33**.

N,N-bis(methyl-*d*₃)pyren-1-amine (**33a**)




Following the general procedure C, the reaction of pyren-1-amine **32a** (43.5 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), $\text{Ni(OAc)}_2 \cdot 4\text{H}_2\text{O}$ (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and $\text{DCM/H}_2\text{O}$ (2 mL, v:v = 20/1) at room temperature for 12 h afford **33a** (42.7 mg, 85%, 99% D) as a yellow solid: ^1H NMR (400 MHz, CDCl_3) δ 8.50 (d, J = 9.2 Hz, 1 H), 8.19 - 8.07 (m, 4 H), 8.04 - 7.92 (m, 3 H), 7.75 (d, J = 8.2 Hz, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 148.9, 131.6, 131.3, 127.3, 126.9, 126.3, 125.97, 125.87, 125.4, 125.2, 124.3, 124.3, 123.4, 116.3. ATR-FTIR (cm^{-1}): 3038, 1598, 1487, 1433, 1278, 1179, 913, 839, 747. HRMS (ESI^+) Calcd for $\text{C}_{18}\text{H}_{10}\text{D}_6\text{N}$ $[\text{M}+\text{H}]^+$: 252.1654, found: 252.1653.

The corresponding non-deuterated product:




N,N-dimethylpyren-1-amine **33a-H**: ^1H NMR (400 MHz, CDCl_3) δ 8.50 (d, $J = 9.2$ Hz, 1 H), 8.20 - 8.06 (m, 4 H), 8.04 - 7.90 (m, 3 H), 7.76 (d, $J = 8.2$ Hz, 1 H), 3.08 (s, 6 H). ^{13}C NMR (101 MHz, CDCl_3) δ 148.9, 131.6, 131.3, 127.3, 127.0, 126.3, 125.97, 125.88, 125.5, 125.2, 124.3, 124.3, 123.4, 116.4, 45.6.

N,N-bis(methyl- d_3)-4-nitronaphthalen-1-amine (**33b**)




Following the general procedure C, the reaction of 4-nitronaphthalen-1-amine **32b** (37.6 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), $\text{Ni}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$ (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and $\text{DCM}/\text{H}_2\text{O}$ (2 mL, v:v = 20/1) at room temperature for 12 h afford **33b** (30.2 mg, 68%, 99% D) as a yellow solid: ^1H NMR (400 MHz, CDCl_3) δ 8.78 (d, $J = 8.8$ Hz, 1 H), 8.30 (d, $J = 8.6$ Hz, 1 H), 8.19 (d, $J = 8.6$ Hz, 1 H), 7.73 - 7.62 (m, 1 H), 7.58 - 7.48 (m, 1 H), 6.89 (d, $J = 8.6$ Hz, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 157.4, 139.4, 129.3, 127.6, 127.4, 126.6, 125.7, 125.5, 124.0, 110.4. ATR-FTIR (cm^{-1}): 3080, 2924, 1505, 1427, 1291, 826, 763, 652. HRMS (ESI^+) Calcd for $\text{C}_{12}\text{H}_7\text{D}_6\text{N}_2\text{O}_2$ [$\text{M}+\text{H}$] $^+$: 223.1348, found: 223.1347.

The corresponding non-deuterated product:




N,N-dimethyl-4-nitronaphthalen-1-amine **33b-H**: ^1H NMR (400 MHz, CDCl_3) δ 8.78 (d, $J = 8.7$ Hz, 1 H), 8.31 (d, $J = 8.6$ Hz, 1 H), 8.20 (d, $J = 8.6$ Hz, 1 H), 7.72 - 7.61 (m, 1 H), 7.59 - 7.49 (m, 1 H), 6.91 (d, $J = 8.6$ Hz, 1 H), 3.04 (s, 6 H). ^{13}C NMR (101 MHz, CDCl_3) δ 157.3, 139.5, 129.3, 127.6, 127.5, 126.6, 125.7, 125.5, 124.0, 110.5, 44.7.

2-(2-(bis(methyl- d_3)amino)phenyl)ethan-1-ol (**33c**)




Following the general procedure C, the reaction of 2-(2-aminophenyl)ethan-1-ol **32c** (27.4 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), Ni(OAc)₂·4H₂O (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and DCM/H₂O (2 mL, v:v = 20/1) at room temperature for 12 h afford **33c** (24.3 mg, 71%, 99% D) as oil: ¹H NMR (500 MHz, CDCl₃) δ 7.27 - 7.20 (m, 1 H), 7.22 - 7.16 (m, 1 H), 7.17 - 7.11 (m, 1 H), 7.11 - 7.04 (m, 1 H), 5.60 (bs, 1 H), 3.93 - 3.74 (m, 2 H), 3.07 - 2.90 (m, 2 H). ¹³C NMR (126 MHz, CDCl₃) δ 152.0, 136.5, 131.2, 127.7, 125.1, 120.0, 64.6, 36.4. ATR-FTIR (cm⁻¹): 3295, 2924, 2854, 1490, 1262, 1045, 936, 760. HRMS (ESI⁺) Calcd for C₁₀H₁₀D₆NO [M+H]⁺: 172.1603, found: 172.1605.

The corresponding non-deuterated product:



2-(2-(dimethylamino)phenyl)ethan-1-ol **33c-H**: ¹H NMR (500 MHz, CDCl₃) δ 7.27 - 7.20 (m, 1 H), 7.23 - 7.17 (m, 2 H), 7.17 - 7.11 (m, 1 H), 7.11 - 7.04 (m, 1 H), 5.51 (bs, 1 H), 3.91 - 3.76 (m, 2 H), 3.06 - 2.92 (m, 2 H), 2.70 (s, 6 H). ¹³C NMR (126 MHz, CDCl₃) δ 152.0, 136.5, 131.2, 127.7, 125.2, 120.1, 64.6, 44.9, 36.4.


3-Fluoro-*N,N*-bis(methyl-*d*₃)-4-morpholinoaniline (**33d**)



Following the general procedure C, the reaction of 3-fluoro-4-morpholinoaniline **32d** (39.2 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), Ni(OAc)₂·4H₂O (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and DCM/H₂O (2 mL, v:v = 20/1) at room temperature for 12 h afford **33d** (28.1 mg, 61%, 99% D) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 6.89 (dd, *J* = 9.8, 8.7 Hz, 1H), 6.54 - 6.37 (m, 2 H), 3.94 - 3.78 (m, 4 H), 3.06 - 2.89 (m, 4 H). ¹³C NMR (101 MHz, CDCl₃) δ 156.9 (d, *J* = 243.7 Hz), 147.8 (d, *J* = 9.9 Hz), 129.9 (d, *J* = 9.7 Hz), 120.0 (d, *J* = 4.8 Hz), 108.1 (d, *J* = 2.7 Hz), 101.4 (d, *J* =


24.8 Hz), 67.2, 51.8. ^{19}F NMR (376 MHz, CDCl_3) δ -122.6. ATR-FTIR (cm^{-1}): 2963, 2852, 1629, 1562, 1520, 1234, 1116, 936, 745. HRMS (ESI $^+$) Calcd for $\text{C}_{12}\text{H}_{12}\text{D}_6\text{FN}_2\text{O}$ $[\text{M}+\text{H}]^+$: 231.1774, found: 231.1771.

The corresponding non-deuterated product:




3-fluoro-*N,N*-dimethyl-4-morpholinoaniline **33d-H**: ^1H NMR (400 MHz, CDCl_3) δ 6.89 (dd, $J = 9.8, 8.7$ Hz, 1 H), 6.55 - 6.36 (m, 2 H), 3.93 - 3.79 (m, 4 H), 3.05 - 2.94 (m, 4 H), 2.89 (s, 6 H). ^{13}C NMR (101 MHz, CDCl_3) δ 156.9 (d, $J = 243.9$ Hz), 147.7 (d, $J = 10.0$ Hz), 129.9 (d, $J = 9.9$ Hz), 120.0 (d, $J = 4.9$ Hz), 108.1 (d, $J = 2.7$ Hz), 101.5 (d, $J = 24.9$ Hz), 67.2, 51.8 (d, $J = 2.3$ Hz), 40.8. ^{19}F NMR (376 MHz, CDCl_3) δ -122.6.

9-Ethyl-*N,N*-bis(methyl- d_3)-9*H*-carbazol-3-amine (**33e**)




Following the general procedure C, the reaction of 9-ethyl-9*H*-carbazol-3-amine **32e** (42.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), $\text{Ni}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$ (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and $\text{DCM}/\text{H}_2\text{O}$ (2 mL, v:v = 20/1) at room temperature for 12 h afford **33e** (36.3 mg, 74%, 99% D) as a yellow solid: ^1H NMR (400 MHz, CDCl_3) δ 8.07 - 8.02 (m, 1 H), 7.54 - 7.47 (m, 1 H), 7.44 - 7.38 (m, 1 H), 7.34 - 7.27 (m, 2 H), 7.18 - 7.07 (m, 2 H), 4.29 (q, $J = 7.2$ Hz, 2 H), 1.38 (t, $J = 7.2$ Hz, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 145.3, 140.3, 134.0, 125.3, 123.4, 122.8, 120.3, 117.9, 115.2, 108.8, 108.3, 105.2, 37.5, 13.8. ATR-FTIR (cm^{-1}): 3049, 2974, 1490, 1472, 1314, 1231, 851, 723. HRMS (ESI $^+$) Calcd for $\text{C}_{16}\text{H}_{13}\text{D}_6\text{N}_2$ $[\text{M}+\text{H}]^+$: 245.1919, found: 245.1918.

The corresponding non-deuterated product:




9-Ethyl-*N,N*-dimethyl-9*H*-carbazol-3-amine **33e-H**: ^1H NMR (400 MHz, CDCl_3) δ 8.11-8.06 (m, 1 H), 7.56 (d, $J = 2.4$ Hz, 1 H), 7.49 - 7.40 (m, 1 H), 7.41 - 7.29 (m, 2 H), 7.24 - 7.11 (m, 2 H), 4.33 (q, $J = 7.2$ Hz, 2 H), 3.02 (s, 4 H), 1.42 (t, $J = 7.2$ Hz, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 145.1, 140.3, 134.2, 125.3, 123.4, 122.8, 120.3, 118.0, 115.4, 108.8, 108.3, 105.5, 43.0, 37.5, 13.9.

N,N-bis(methyl- d_3)-1*H*-indol-5-amine (**33f**)




Following the general procedure C, the reaction of 1*H*-indol-5-amine **32f** (26.4 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), $\text{Ni}(\text{OAc})_2 \cdot 4\text{H}_2\text{O}$ (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and $\text{DCM}/\text{H}_2\text{O}$ (2 mL, v:v = 20/1) at room temperature for 12 h afford **33f** (15.2 mg, 46%, 99% D) as oil: ^1H NMR (400 MHz, CDCl_3) δ 8.05 (s, 1 H), 7.28 (d, $J = 8.8$ Hz, 1 H), 7.13 (t, $J = 2.8$ Hz, 1 H), 7.07 (d, $J = 2.0$ Hz, 1 H), 6.92 (dd, $J = 8.8, 2.4$ Hz, 1 H), 6.49 - 6.42 (m, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 146.0, 130.3, 128.5, 124.5, 113.1, 111.3, 104.9, 102.0. ATR-FTIR (cm^{-1}): 3404, 1578, 1474, 1322, 1255, 1185, 752, 723. HRMS (ESI $^+$) Calcd for $\text{C}_{10}\text{H}_7\text{D}_6\text{N}_2$ [$\text{M}+\text{H}$] $^+$: 167.1450, found: 167.1449.

The corresponding non-deuterated product:




N,N-dimethyl-1*H*-indol-5-amine **33f-H**: ^1H NMR (400 MHz, CDCl_3) δ 8.02 (s, 1 H), 7.28 (d, $J = 8.8$ Hz, 1 H), 7.14 (t, $J = 2.8$ Hz, 1 H), 7.07 (d, $J = 2.3$ Hz, 1 H), 6.93 (dd, $J = 8.8, 2.4$ Hz, 1 H), 6.50 - 6.42 (m, 1 H), 2.94 (s, 6 H). ^{13}C NMR (101 MHz, CDCl_3) δ 146.1, 130.3, 128.5, 124.5, 113.2, 111.3, 104.9, 102.0, 43.0.

(*E*)-*N,N*-bis(methyl- d_3)-4-(phenyldiazenyl)aniline (**33g**)




Following the general procedure C, the reaction of (*E*)-4-(phenyldiazenyl)aniline **32g** (39.4 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), Ni(OAc)₂·4H₂O (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and DCM/H₂O (2 mL, v:v = 20/1) at room temperature for 12 h afford **33g** (34.5 mg, 75%, 99% D) as a yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 7.95 - 7.80 (m, 4 H), 7.54 - 7.44 (m, 2 H), 7.44 - 7.35 (m, 1 H), 6.81 - 6.70 (m, 2 H). ¹³C NMR (101 MHz, CDCl₃) δ 153.2, 152.4, 143.6, 129.3, 128.9, 124.9, 122.2, 111.4. ATR-FTIR (cm⁻¹): 3064, 3022, 1599, 1512, 1373, 1149, 913, 818, 747. HRMS (ESI⁺) Calcd for C₁₄H₁₀D₆N₃ [M+H]⁺: 232.1715, found: 232.1715.

The corresponding non-deuterated product:



(*E*)-*N,N*-dimethyl-4-(phenyldiazenyl)aniline **33g-H**: ¹H NMR (400 MHz, CDCl₃) δ 7.95 - 7.82 (m, 4 H), 7.54 - 7.44 (m, 2 H), 7.43 - 7.35 (m, 1 H), 6.81 - 6.72 (m, 2 H), 3.08 (s, 6 H). ¹³C NMR (101 MHz, CDCl₃) δ 153.2, 152.4, 143.6, 129.3, 128.9, 124.9, 122.2, 111.5, 40.3.


N,N-bis(methyl-*d*₃)-2,2-diphenylpropan-1-amine (**33h**)



Following the general procedure C, the reaction of 2,2-diphenylpropan-1-amine hydrochloride **32h** (49.4 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), Ni(OAc)₂·4H₂O (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and DCM/H₂O (2 mL, v:v = 20/1) at room temperature for 12 h afford **33h** (30.1 mg, 61%, 99% D) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 7.29 - 7.20 (m, 4 H), 7.19 - 7.13 (m, 1 H), 3.01 (s, 1 H). ¹³C NMR (101 MHz, CDCl₃) δ 148.9, 127.8, 127.6, 125.6, 70.1, 26.7. ATR-FTIR


(cm⁻¹): 3025, 2967, 2935, 1494, 1444, 1200, 913, 746, 698. HRMS (ESI⁺) Calcd for C₁₇H₁₆D₆N [M+H]⁺: 246.2123, found: 246.2123.

The corresponding non-deuterated product:




N,N-dimethyl-2,2-diphenylpropan-1-amine **33h-H**: ¹H NMR (400 MHz, CDCl₃) δ 7.29 - 7.20 (m, 4 H), 7.20 - 7.13 (m, 1 H), 3.02 (s, 1 H), 2.02 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ 148.9, 127.8, 127.6, 125.6, 70.2, 48.4, 26.7.

N,N-bis(methyl-*d*₃)-9*H*-fluoren-9-amine (**33i**)




Following the general procedure C, the reaction of 9*H*-fluoren-9-amine **32i** (36.2 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), Ni(OAc)₂·4H₂O (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and DCM/H₂O (2 mL, v:v = 20/1) at room temperature for 12 h afford **33i** (22.0 mg, 51%, 99% D) as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.70 (dt, *J* = 7.5, 0.9 Hz, 2 H), 7.64 (dd, *J* = 7.4, 1.0 Hz, 2 H), 7.42 - 7.34 (m, 1 H), 7.30 (td, *J* = 7.4, 1.2 Hz, 2 H), 4.85 (s, 1 H). ¹³C NMR (101 MHz, CDCl₃) δ 144.0, 141.0, 128.0, 127.0, 125.9, 119.7, 70.1. ATR-FTIR (cm⁻¹): 2957, 2931, 1498, 1456, 1361, 1174, 882, 705. HRMS (ESI⁺) Calcd for C₁₅H₁₀D₆N [M+H]⁺: 216.1654, found: 216.1653.

The corresponding non-deuterated product:




N,N-dimethyl-9*H*-fluoren-9-amine **33i-H**: ¹H NMR (400 MHz, CDCl₃) δ 7.70 (dt, *J* = 7.5, 0.9 Hz, 2 H), 7.64 (dd, *J* = 7.4, 1.0 Hz, 2 H), 7.42 - 7.35 (m, 2 H), 7.30 (td, *J* = 7.5, 1.2 Hz, 2 H), 4.86 (s, 1 H), 2.35 (s, 6 H). ¹³C NMR (101 MHz, CDCl₃) δ 143.9, 141.0, 128.0, 127.0, 125.9, 119.7, 70.2, 41.2.

N-(4-(bis(methyl-*d*₃)amino)-2,5-diethoxyphenyl)benzamide (**33j**)




Following the general procedure C, the reaction of *N*-(4-amino-2,5-diethoxyphenyl)benzamide **32j** (60.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), Ni(OAc)₂·4H₂O (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0 equiv), and DCM/H₂O (2 mL, v:v = 20/1) at room temperature for 12 h afford **33j** (51.5 mg, 77%, 99% D) as a white solid: ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 1 H), 8.25 (s, 1 H), 7.93 - 7.82 (m, 2 H), 7.57 - 7.44 (m, 3 H), 6.56 (s, 1 H), 4.20 - 4.05 (m, 4 H), 1.52 - 1.40 (m, 6 H). ¹³C NMR (101 MHz, CDCl₃) δ 164.6, 145.3, 141.3, 138.2, 131.5, 128.7, 126.8, 122.1, 105.4, 103.3, 65.2, 64.0, 15.1, 14.9. ATR-FTIR (cm⁻¹): 3430, 2978, 2930, 1669, 1522, 1419, 1243, 1202, 1046, 913, 708. HRMS (ESI⁺) Calcd for C₁₉H₁₉D₆N₂O₃ [M+H]⁺: 335.2236, found: 335.2237.

The corresponding non-deuterated product:



N-(4-(dimethylamino)-2,5-diethoxyphenyl)benzamide **33j-H**: ¹H NMR (400 MHz, CDCl₃) δ 8.50 (s, 1 H), 8.25 (s, 1 H), 7.91 - 7.83 (m, 2 H), 7.54 - 7.45 (m, 3 H), 6.57 (s, 1 H), 4.18 - 4.09 (m, 4 H), 2.80 (s, 6 H), 1.52 - 1.40 (m, 6 H). ¹³C NMR (101 MHz, CDCl₃) δ 164.6, 145.4, 141.3, 138.2, 135.3, 131.5, 128.7, 126.8, 122.2, 105.4, 103.4, 65.2, 64.0, 43.3, 15.1, 14.9.


3-(4-(Bis(methyl-*d*₃)amino)phenyl)-3-ethylpiperidine-2,6-dione (**33k**)



Following the general procedure C, the reaction of aminoglutethimide **32k** (46.4 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), Ni(OAc)₂·4H₂O (5.0 mg, 0.02 mmol, 0.1 equiv), KF

(23.2 mg, 0.4 mmol, 2.0 equiv), and DCM/H₂O (2 mL, v:v = 20/1) at room temperature for 12 h afford **33k** (36.1 mg, 68%, 99% D) as a white solid: ¹H NMR (500 MHz, CDCl₃) δ 8.05 (s, 1 H), 7.12 (d, *J* = 8.9 Hz, 2 H), 6.68 (d, *J* = 8.9 Hz, 2 H), 2.62 - 2.53 (m, 1 H), 2.52 - 2.41 (m, 1 H), 2.37 - 2.29 (m, 1 H), 2.22 - 2.12 (m, 1 H), 2.06 - 1.95 (m, 1 H), 1.94 - 1.83 (m, 1 H), 0.85 (t, *J* = 7.4 Hz, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 175.7, 172.6 149.7, 126.9, 125.6, 112.5, 50.1, 32.9, 29.4, 26.9, 9.0. ATR-FTIR (cm⁻¹): 3291, 3190, 3028, 1659, 1529, 1451, 1275, 1016, 765, 749. HRMS (ESI⁺) Calcd for C₁₅H₁₅D₆N₂O₂ [M+H]⁺: 267.1974, found: 267.1974.

The corresponding non-deuterated product:




33k-H

3-(4-(dimethylamino)phenyl)-3-ethylpiperidine-2,6-dione **33k-H**:

¹H NMR (400 MHz, CDCl₃) δ 7.97 (s, 1 H), 7.12 (d, *J* = 8.9 Hz, 2 H), 6.69 (d, *J* = 8.9 Hz, 2 H), 2.94 (s, 6 H), 2.64 - 2.52 (m, 1 H), 2.53 - 2.39 (m, 1 H), 2.39 - 2.28 (m, 1 H), 2.24 - 2.11 (m, 1 H), 2.08 - 1.94 (m, 1 H), 1.96 - 1.81 (m, 1 H), 0.85 (t, *J* = 7.4 Hz, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ 175.6, 172.6, 149.7, 126.9, 125.7, 112.6, 50.1, 40.4, 32.9, 29.4, 26.9, 9.0.

4-(bis(methyl-*d*₃)amino)-1,5-dimethyl-2-phenyl-1,2-dihydro-3*H*-pyrazol-3-one (**33l**)




33l

Following the general procedure C, the reaction of 4-aminoantipyrene **32l** (40.6 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), Ni(OAc)₂·4H₂O (5.0 mg, 0.02 mmol, 0.1 equiv), KF (23.2 mg, 0.4 mmol, 2.0


equiv), and DCM/H₂O (2 mL, v:v = 20/1) at room temperature for 12 h afford **33l** (19.4 mg, 41%, 99% D) as a yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 7.45 - 7.36 (m, 4 H), 7.25 - 7.19 (m, 1 H), 2.94 (s, 3 H), 2.19 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ 163.6, 150.1, 135.3, 128.9, 125.8, 123.1, 36.7, 10.3. ATR-FTIR (cm⁻¹):

3025, 2911, 1657, 1593, 1458, 1504, 758, 698. HRMS (ESI⁺) Calcd for C₁₃H₁₂D₆N₃O [M+H]⁺: 238.1821, found: 238.1821.


The corresponding non-deuterated product:



N-(methyl-*d*₃)-*N*-phenylaniline (**33m**)




The corresponding non-deuterated product:




Section S7. Pd-catalyzed C–H bond methylation-d3

General Procedure D:




The 25 mL Schlenk tube was purged with argon for three times. Then the tube was added substrates **34** (0.2 mmol, 1.0 equiv), **DMTT** (0.24-0.6 mmol, 1.2-3.0 equiv), Pd(OAc)₂ (4.5 mg, 0.02 mmol, 0.1 equiv), Cu(OAc)₂ (43.6 mg, 0.24 mmol, 1.2 equiv), TFA (74.3 μL, d = 1.535 g/mL, 1.0 mmol, 5.0 equiv), and DCE (2 mL). The mixture was stirring at 60 °C for 12 hours. Then the resulting mixture was cooled down and concentrated in vacuo. The residue was purified by column chromatography to afford the corresponding product **35**.

2-(4-Methyl-2,6-bis(methyl-*d*₃)phenyl)pyridine (**35a**)




Following the general procedure D, the reaction of 2-(*p*-tolyl)pyridine **34a** (33.8 mg, 0.2 mmol, 1.0 equiv), **DMTT** (210.6 mg, 0.6 mmol, 3.0 equiv), Pd(OAc)₂ (4.5 mg, 0.02 mmol, 0.1 equiv), Cu(OAc)₂ (43.6 mg, 0.24 mmol, 1.2 equiv), TFA (74.3 μL, d = 1.535 g/mL, 1.0 mmol, 5.0 equiv), and DCE (2 mL) at 60 °C for 12 hours afford **35a** (25.1 mg, 62%, 99% D) as oil: ¹H NMR (400 MHz, CDCl₃) δ 8.72 (s, 1 H), 7.74 (td, *J* = 7.6, 1.8 Hz, 1 H), 7.26 - 7.17 (m, 2 H), 6.93 (s, 2 H), 2.32 (s, 3 H). ¹³C NMR (101 MHz, CDCl₃) δ 160.0, 149.5, 137.7, 137.3, 136.1, 135.5, 128.2, 124.7, 121.5, 21.1. ATR-FTIR (cm⁻¹): 3004, 2921, 1608, 1586, 1563, 1451, 1424, 913, 712. HRMS (ESI⁺) Calcd for C₁₄H₁₀D₆N [M+H]⁺: 204.1654, found: 204.1654.

The corresponding non-deuterated product:




2-Mesitylpyridine **35a-H**: ^1H NMR (400 MHz, CDCl_3) δ 8.71 (s, 1 H), 7.75 (td, $J = 7.7, 1.8$ Hz, 1 H), 7.28 - 7.16 (m, 3 H), 6.93 (s, 2 H), 2.32 (s, 3 H), 2.01 (s, 6 H). ^{13}C NMR (101 MHz, CDCl_3) δ 160.0, 149.5, 137.4, 136.3, 135.6, 128.2, 124.7, 121.5, 21.1, 20.1.

3-Methyl-2-(2-(methyl- d_3)phenyl)pyridine (**35b**)




Following the general procedure D, the reaction of 3-methyl-2-phenylpyridine **34b** (33.8 mg, 0.2 mmol, 1.0 equiv), **DMTT** (105.3 mg, 0.3 mmol, 1.5 equiv), $\text{Pd}(\text{OAc})_2$ (4.5 mg, 0.02 mmol, 0.1 equiv), $\text{Cu}(\text{OAc})_2$ (43.6 mg, 0.24 mmol, 1.2 equiv), TFA (74.3 μL , $d = 1.535$ g/mL, 1.0 mmol, 5.0 equiv), and DCE (2 mL) at 60 $^\circ\text{C}$ for 12 hours afford **35b** (24.2 mg, 65%, 99% D) as oil: ^1H NMR (400 MHz, CDCl_3) δ 8.51 (dd, $J = 5.0, 1.6$ Hz, 1 H), 7.63 - 7.54 (m, 1 H), 7.31 - 7.22 (m, 3 H), 7.23 - 7.12 (m, 2 H), 2.11 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 146.7, 137.7, 130.1, 128.4, 127.9, 125.7, 122.1, 19.0. ATR-FTIR (cm^{-1}): 2599, 2853, 1566, 1447, 1276, 1261, 913, 790, 748. HRMS (ESI $^+$) Calcd for $\text{C}_{13}\text{H}_{11}\text{D}_3\text{N}$ $[\text{M}+\text{H}]^+$: 187.1309, found: 187.1309.

The corresponding non-deuterated product:



3-Methyl-2-(*o*-tolyl)pyridine **35b-H**: ^1H NMR (400 MHz, CDCl_3) δ 8.50 (dd, $J = 4.9, 1.6$ Hz, 1 H), 7.64 - 7.54 (m, 1 H), 7.31 - 7.23 (m, 3 H), 7.21 - 7.13 (m, 2 H), 2.10 (s, 3 H), 2.08 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 159.6, 146.7, 140.2, 137.7, 135.5, 131.5, 130.1, 128.4, 127.9, 125.7, 122.1, 29.7, 19.3, 19.0.


N-(2-(Methyl- d_3)phenyl)acetamide (**35c**)



Following the general procedure D, the reaction of *N*-phenylacetamide **34a** (27.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (84.2 mg, 0.24 mmol, 1.2 equiv), $\text{Pd}(\text{OAc})_2$ (4.5 mg, 0.02 mmol, 0.1 equiv), $\text{Cu}(\text{OAc})_2$ (43.6 mg, 0.24 mmol, 1.2 equiv), TFA (74.3 μL , $d = 1.535$ g/mL, 1.0 mmol, 5.0 equiv), and DCE (2 mL) at 60 $^\circ\text{C}$ for 12 hours afford **35c** (20.7


mg, 68%, 99% D) as oil: ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, $J = 7.9$ Hz, 1 H), 7.24 - 7.13 (m, 3 H), 7.12 - 7.02 (m, 1 H), 2.17 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.5, 135.6, 130.4, 129.6, 126.6, 125.4, 123.6, 24.1. ATR-FTIR (cm^{-1}): 3178, 3083, 1687, 1364, 1271, 1198, 913, 748. HRMS (ESI^+) Calcd for $\text{C}_9\text{H}_9\text{D}_3\text{NO}$ $[\text{M}+\text{H}]^+$: 153.1102, found: 153.1100.

The corresponding non-deuterated product:




N-(*o*-tolyl)acetamide **35c-H**: ^1H NMR (400 MHz, CDCl_3) δ 7.70 (d, $J = 8.0$ Hz, 1 H), 7.24 - 7.11 (m, 3 H), 7.12 - 7.02 (m, 1 H), 2.24 (s, 3 H), 2.18 (s, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 168.4, 135.6, 130.4, 129.6, 126.6, 125.3, 123.6, 24.2, 17.7.

N-(4-Ethoxy-2-(methyl- d_3)phenyl)acetamide (**35d**)



Following the general procedure D, the reaction of *N*-(4-ethoxyphenyl)acetamide **34d** (35.8 mg, 0.2 mmol, 1.0 equiv), **DMTT** (84.2 mg, 0.24 mmol, 1.2 equiv), $\text{Pd}(\text{OAc})_2$ (4.5 mg, 0.02 mmol, 0.1 equiv), $\text{Cu}(\text{OAc})_2$ (43.6 mg, 0.24 mmol, 1.2 equiv), TFA (74.3 μL , $d = 1.535$ g/mL, 1.0 mmol, 5.0 equiv), and DCE (2 mL) at 60 $^\circ\text{C}$ for 12 hours afford **35d** (29.5 mg, 75%, 99% D) as oil: ^1H NMR (400 MHz, CDCl_3) δ 7.35 (d, $J = 8.3$ Hz, 1 H), 7.24 - 6.96 (m, 1 H), 6.78 - 6.55 (m, 2 H), 3.97 (q, $J = 7.1$ Hz, 2 H), 2.13 (s, 3 H), 1.38 (t, $J = 7.0$ Hz, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ 169.1, 156.8, 133.0, 128.3, 126.2, 116.4, 112.0, 63.5, 14.8. ATR-FTIR (cm^{-1}): 3271, 2980, 2928, 1657, 1531, 1479, 1287, 1180, 1049, 913, 746. HRMS (ESI^+) Calcd for $\text{C}_{11}\text{H}_{13}\text{D}_3\text{NO}_2$ $[\text{M}+\text{H}]^+$: 197.1364, found: 197.1364.

The corresponding non-deuterated product:




N-(4-Ethoxy-2-methylphenyl)acetamide **35d-H**: ^1H NMR (400 MHz, CDCl_3) δ 7.39 (d, $J = 8.3$ Hz, 1 H), 7.20 - 7.90 (m, 1 H), 6.80 - 6.53 (m, 2 H), 3.98 (q, $J = 6.9$ Hz, 2 H), 2.19 (s, 3 H), 2.15 (s, 3 H), 1.38 (t, $J = 7.0$ Hz, 3 H). ^{13}C NMR (101 MHz, CDCl_3) δ

169.1, 156.8, 133.0, 128.3, 126.2, 116.5, 112.1, 63.5, 18.1, 14.8.


Section S8. Methylenation of trifluoromethyl substituted alkenes

General Procedure E:



The 25 mL Schlenk tube was purged with argon for three times. Then the tube was added substrates **36** (0.2 mmol, 1.0 equiv), **DMTT** (0.4 mmol, 2.0 equiv), KHMDS (0.4 mmol, 2.0 equiv), and THF (2 mL). The reaction was stirring at room temperature for 12 hours. Then the resulting mixture was concentrated in vacuo and the residue was purified by column chromatography to afford the corresponding product **37**.


2-Methoxy-6-(1-(trifluoromethyl)cyclopropyl-2,2-*d*₂)naphthalene (**37a**)



Following the general procedure E, the reaction of 2-methoxy-6-(3,3,3-trifluoroprop-1-en-2-yl)naphthalene **36a** (50.4 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), KHMDS (0.4 mL, 1.0 M in THF, 0.4 mmol, 2.0 equiv), and THF (2 mL) at room temperature for 12 hours afford **37a** (38.4 mg, 72%, 99% D) as oil: ¹H NMR (400 MHz, CDCl₃) δ 7.87 - 7.77 (m, 1 H), 7.75 - 7.68 (m, 2 H), 7.56 - 7.44 (m, 1 H), 7.18 - 7.12 (m, 2 H), 3.92 (s, 3 H), 1.42 - 1.36 (m, 1 H), 1.19 - 1.01 (m, 1 H). ¹³C NMR (101 MHz, CDCl₃) δ 158.1, 134.3, 131.4, 130.4, 129.9, 129.4, 129.2, 126.8, 126.6 (q, J = 273.3 Hz), 119.2, 105.5, 55.3,

9.6 (q, $J = 2.5$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -69.9. ATR-FTIR (cm^{-1}): 3008, 2940, 1608, 1487, 1353, 1263, 1198, 913, 747. HRMS (ESI⁺) Calcd for $\text{C}_{15}\text{H}_{12}\text{D}_2\text{F}_3\text{O}$ $[\text{M}+\text{H}]^+$: 269.1117, found: 269.1110.


The corresponding non-deuterated product:



2-Methoxy-6-(1-(trifluoromethyl)cyclopropyl)naphthalene
37a-H: ^1H NMR (400 MHz, CDCl_3) δ 7.86 - 7.77 (m, 1 H),
7.74 - 7.68 (m, 2 H), 7.54 - 7.45 (m, 1 H), 7.18 - 7.12 (m,
2 H), 3.92 (s, 3 H), 1.43 - 1.37 (m, 2 H), 1.18 - 1.05 (m, 2

H). ^{13}C NMR (101 MHz, CDCl_3) δ 158.1, 134.3, 131.2, 130.4, 129.9, 129.4, 129.2, 126.8, 126.5 (q, $J = 273.4$ Hz), 119.2, 105.5, 55.3, 9.8 (q, $J = 2.6$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -70.0.


5-(1-(Trifluoromethyl)cyclopropyl-2,2- d_2)benzo[*d*][1,3]dioxole (**37b**)



Following the general procedure *E*, the reaction of
5-(3,3,3-trifluoroprop-1-en-2-yl)benzo[*d*][1,3]dioxole **36b** (43.2
mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0
equiv), KHMDS (0.4 mL, 1.0 M in THF, 0.4 mmol, 2.0 equiv),

and THF (2 mL) at room temperature for 12 hours afford **37b** (23.1 mg, 50%, 99% D)
as oil: ^1H NMR (400 MHz, CDCl_3) δ 6.97 - 6.83 (m, 2 H), 6.80 - 6.71 (m, 1 H), 5.96
(s, 2 H), 1.33 - 1.26 (m, 1 H), 1.04 - 0.91 (m, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ
147.6, 147.4, 124.9, 111.6, 108.0, 101.2. ^{19}F NMR (376 MHz, CDCl_3) δ -70.42.
ATR-FTIR (cm^{-1}): 2989, 2924, 1508, 1275, 1261, 1136, 1041, 913, 748. HRMS
(ESI⁺) Calcd for $\text{C}_{11}\text{H}_8\text{D}_2\text{F}_3\text{O}_2$ $[\text{M}+\text{H}]^+$: 233.0753, found: 233.0750.


The corresponding non-deuterated product:



5-(1-(Trifluoromethyl)cyclopropyl)benzo[*d*][1,3]dioxole **37b-H**:
 ^1H NMR (400 MHz, CDCl_3) δ 6.95 - 6.87 (m, 2 H), 6.78 - 6.72
(m, 1 H), 5.96 (s, 2 H), 1.34 - 1.26 (m, 2 H), 1.09 - 0.91 (m, 2 H).
 ^{13}C NMR (101 MHz, CDCl_3) δ 124.9, 111.6, 108.0, 101.2, 10.0

(q, $J = 2.4$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -70.43.


1-Bromo-4-(1-(trifluoromethyl)cyclopropyl-2,2- d_2)benzene (**37c**)



37c

Following the general procedure *E*, the reaction of 1-bromo-4-(3,3,3-trifluoroprop-1-en-2-yl)benzene **36c** (50.0 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), **KHMDS** (0.4 mL, 1.0 M in THF, 0.4 mmol, 2.0 equiv), and THF (2 mL) at room temperature for 12 hours afford **37c** (34.0 mg, 64%, 99% D) as oil: ^1H NMR (400 MHz, CDCl_3) δ 7.51 - 7.43 (m, 2 H), 7.37 - 7.25 (m, 2 H), 1.39 - 1.31 (m, 1 H), 1.01 - 0.96 (m, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 135.1, 132.9, 131.5, 126.0 (q, $J = 273.4$ Hz), 122.5, 9.6 (q, $J = 2.2$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -70.2. ATR-FTIR (cm^{-1}): 2990, 1491, 1348, 1157, 1012, 913, 825, 747. HRMS (ESI⁺) Calcd for $\text{C}_{10}\text{H}_7\text{D}_2\text{BrF}_3$ [$\text{M}+\text{H}$]⁺: 266.9950, found: 266.9956.


The corresponding non-deuterated product:



37c-H

1-Bromo-4-(1-(trifluoromethyl)cyclopropyl)benzene **37c-H**: ^1H NMR (400 MHz, CDCl_3) δ 7.51 - 7.43 (m, 2 H), 7.35 - 7.26 (m, 2 H), 1.39 - 1.31 (m, 2 H), 1.11 - 0.93 (m, 2 H). ^{13}C NMR (101 MHz, CDCl_3) δ 135.1, 132.9, 131.5, 126.0 (q, $J = 273.4$ Hz), 122.5, 9.75 (q, $J = 1.6$ Hz). ^{19}F NMR (376 MHz, CDCl_3) δ -70.2.

1-Methyl-3-(1-(trifluoromethyl)cyclopropyl-2,2- d_2)benzene (**37d**)




37d

Following the general procedure *E*, the reaction of 1-methyl-3-(3,3,3-trifluoroprop-1-en-2-yl)benzene **36d** (37.2 mg, 0.2 mmol, 1.0 equiv), **DMTT** (140.4 mg, 0.4 mmol, 2.0 equiv), **KHMDS** (0.4 mL, 1.0 M in THF, 0.4 mmol, 2.0 equiv), and THF (2 mL) at room temperature for 12 hours afford **37d** (27.5 mg, 68%, 99% D) as oil: ^1H NMR (400 MHz, CDCl_3) δ 7.29 - 7.20 (m, 3 H), 7.16 - 7.11 (m, 1 H), 2.36 (s, 3 H), 1.35 - 1.28 (m, 2 H), 1.06 - 0.97 (m, 1 H). ^{13}C NMR (101 MHz, CDCl_3) δ 138.0, 132.7, 132.0, 129.0, 128.3, 128.2, 126.4 (q, $J = 273.3$ Hz), 21.3, 9.5 (q, $J = 2.6$ Hz).

ATR-FTIR (cm⁻¹): 3027, 2925, 1610, 1491, 1352, 1218, 913, 785, 746. HRMS (ESI⁺)

Calcd for C₁₁H₁₀D₂F₃ [M+H]⁺: 203.1011, found: 203.1005.

The corresponding non-deuterated product:



37d-H

1-Methyl-3-(1-(trifluoromethyl)cyclopropyl)benzene **37d-H**: ¹H


NMR (400 MHz, CDCl₃) δ 7.31 - 7.18 (m, 3 H), 7.16 - 7.10 (m, 1

H), 2.36 (s, 3 H), 1.36 - 1.31 (m, 2 H), 1.10 - 0.95 (m, 2 H). ¹³C

NMR (101 MHz, CDCl₃) δ 138.0 132.7, 132.0, 129.0, 128.3, 128.2, 126.4 (q, *J* =


273.4 Hz), 21.3, 9.6 (q, *d* = 1.7 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -70.1.

Section S9. Crystallographic Data



21b

≡



CCDC: 1892897

Crystal data and structure refinement:

Empirical formula	C ₂₁ H ₂₆ O ₂
Formula weight	310.42
Temperature	173(2) K
Wavelength	1.54178 Å
Crystal system	Monoclinic
Space group	P2 ₁
Unit cell dimensions	<i>a</i> = 6.8051(6) Å <i>α</i> = 90°. <i>b</i> = 39.706(4) Å <i>β</i> = 117.644(4)°. <i>c</i> = 6.9518(6) Å <i>γ</i> = 90°.
Volume	1664.0(3) Å ³

Z	4
Density (calculated)	1.239 Mg/m ³
Absorption coefficient	0.604 mm ⁻¹
F(000)	672
Crystal size	0.190 x 0.180 x 0.150 mm ³
Theta range for data collection	4.454 to 68.548°.
Index ranges	-7<=h<=8, -45<=k<=47, -8<=l<=7
Reflections collected	9682
Independent reflections	5231 [R(int) = 0.0468]
Completeness to theta = 67.679°	98.2 %
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	5231 / 1 / 421
Goodness-of-fit on F ²	1.166
Final R indices [I>2sigma(I)]	R1 = 0.0739, wR2 = 0.1984
R indices (all data)	R1 = 0.0743, wR2 = 0.1986
Absolute structure parameter	0.13(13)
Extinction coefficient	n/a
Largest diff. peak and hole	0.370 and -0.344 e.Å ⁻³

Bond lengths [Å] and angles [°]:

C(1)-O(1)	1.438(8)	C(3)-H(3A)	0.9500
C(1)-H(1A)	0.9800	C(4)-C(5)	1.393(9)
C(1)-H(1B)	0.9800	C(4)-H(4)	0.9500
C(1)-H(1C)	0.9800	C(5)-C(6)	1.405(8)
C(2)-O(1)	1.367(8)	C(5)-C(11)	1.521(9)
C(2)-C(3)	1.389(9)	C(6)-C(7)	1.399(9)
C(2)-C(7)	1.390(9)	C(6)-C(8)	1.520(8)
C(3)-C(4)	1.387(9)	C(7)-H(7)	0.9500

C(8)-C(9)	1.512(9)	C(17)-H(17B)	0.9900
C(8)-H(8A)	0.9900	C(18)-O(2)	1.412(8)
C(8)-H(8B)	0.9900	C(18)-C(20)	1.477(10)
C(9)-C(10)	1.522(8)	C(19)-H(19A)	0.9800
C(9)-H(9A)	0.9900	C(19)-H(19B)	0.9800
C(9)-H(9B)	0.9900	C(19)-H(19C)	0.9800
C(10)-C(15)	1.519(8)	C(20)-C(21)	1.185(11)
C(10)-C(11)	1.560(8)	C(21)-H(21)	0.9500
C(10)-H(10)	1.0000	C(22)-O(4)	1.421(8)
C(11)-C(12)	1.532(8)	C(22)-H(22A)	0.9800
C(11)-H(11)	1.0000	C(22)-H(22B)	0.9800
C(12)-C(13)	1.543(9)	C(22)-H(22C)	0.9800
C(12)-H(12A)	0.9900	C(23)-O(4)	1.360(8)
C(12)-H(12B)	0.9900	C(23)-C(24)	1.391(9)
C(13)-C(14)	1.517(9)	C(23)-C(28)	1.391(8)
C(13)-H(13A)	0.9900	C(24)-C(25)	1.388(9)
C(13)-H(13B)	0.9900	C(24)-H(24)	0.9500
C(14)-C(19)	1.537(9)	C(25)-C(26)	1.394(8)
C(14)-C(15)	1.540(8)	C(25)-H(25)	0.9500
C(14)-C(18)	1.580(9)	C(26)-C(27)	1.414(8)
C(15)-C(16)	1.541(9)	C(26)-C(29)	1.531(8)
C(15)-H(15)	1.0000	C(27)-C(28)	1.398(9)
C(16)-C(17)	1.550(9)	C(27)-C(32)	1.504(8)
C(16)-H(16A)	0.9900	C(28)-H(28)	0.9500
C(16)-H(16B)	0.9900	C(29)-C(33)	1.535(8)
C(17)-C(18)	1.546(9)	C(29)-C(30)	1.539(8)
C(17)-H(17A)	0.9900	C(29)-H(29)	1.0000


C(30)-C(31)	1.518(9)	C(40)-H(40A)	0.9800
C(30)-C(36)	1.524(8)	C(40)-H(40B)	0.9800
C(30)-H(30)	1.0000	C(40)-H(40C)	0.9800
C(31)-C(32)	1.529(9)	C(41)-C(42)	1.179(10)
C(31)-H(31A)	0.9900	C(42)-H(42)	0.9500
C(31)-H(31B)	0.9900	O(2)-H(2)	0.8400
C(32)-H(32A)	0.9900	O(3)-H(3)	0.8400
C(32)-H(32B)	0.9900	O(1)-C(1)-H(1A)	109.5
C(33)-C(34)	1.541(9)	O(1)-C(1)-H(1B)	109.5
C(33)-H(33A)	0.9900	H(1A)-C(1)-H(1B)	109.5
C(33)-H(33B)	0.9900	O(1)-C(1)-H(1C)	109.5
C(34)-C(35)	1.542(8)	H(1A)-C(1)-H(1C)	109.5
C(34)-H(34A)	0.9900	H(1B)-C(1)-H(1C)	109.5
C(34)-H(34B)	0.9900	O(1)-C(2)-C(3)	115.8(5)
C(35)-C(36)	1.540(9)	O(1)-C(2)-C(7)	125.0(6)
C(35)-C(40)	1.543(9)	C(3)-C(2)-C(7)	119.1(6)
C(35)-C(39)	1.556(9)	C(4)-C(3)-C(2)	119.7(6)
C(36)-C(37)	1.535(9)	C(4)-C(3)-H(3A)	120.2
C(36)-H(36)	1.0000	C(2)-C(3)-H(3A)	120.2
C(37)-C(38)	1.543(10)	C(3)-C(4)-C(5)	122.5(6)
C(37)-H(37A)	0.9900	C(3)-C(4)-H(4)	118.7
C(37)-H(37B)	0.9900	C(5)-C(4)-H(4)	118.7
C(38)-C(39)	1.559(9)	C(4)-C(5)-C(6)	117.3(6)
C(38)-H(38A)	0.9900	C(4)-C(5)-C(11)	121.6(5)
C(38)-H(38B)	0.9900	C(6)-C(5)-C(11)	121.2(5)
C(39)-O(3)	1.451(8)	C(7)-C(6)-C(5)	120.5(5)
C(39)-C(41)	1.474(9)	C(7)-C(6)-C(8)	117.3(5)

C(5)-C(6)-C(8)	122.3(6)	C(10)-C(11)-H(11)	107.1
C(2)-C(7)-C(6)	120.9(6)	C(11)-C(12)-C(13)	112.5(5)
C(2)-C(7)-H(7)	119.6	C(11)-C(12)-H(12A)	109.1
C(6)-C(7)-H(7)	119.6	C(13)-C(12)-H(12A)	109.1
C(9)-C(8)-C(6)	113.2(5)	C(11)-C(12)-H(12B)	109.1
C(9)-C(8)-H(8A)	108.9	C(13)-C(12)-H(12B)	109.1
C(6)-C(8)-H(8A)	108.9	H(12A)-C(12)-H(12B)	107.8
C(9)-C(8)-H(8B)	108.9	C(14)-C(13)-C(12)	110.1(5)
C(6)-C(8)-H(8B)	108.9	C(14)-C(13)-H(13A)	109.6
H(8A)-C(8)-H(8B)	107.8	C(12)-C(13)-H(13A)	109.6
C(8)-C(9)-C(10)	110.6(5)	C(14)-C(13)-H(13B)	109.6
C(8)-C(9)-H(9A)	109.5	C(12)-C(13)-H(13B)	109.6
C(10)-C(9)-H(9A)	109.5	H(13A)-C(13)-H(13B)	108.2
C(8)-C(9)-H(9B)	109.5	C(13)-C(14)-C(19)	110.9(5)
C(10)-C(9)-H(9B)	109.5	C(13)-C(14)-C(15)	109.2(5)
H(9A)-C(9)-H(9B)	108.1	C(19)-C(14)-C(15)	113.5(5)
C(15)-C(10)-C(9)	113.2(5)	C(13)-C(14)-C(18)	116.4(5)
C(15)-C(10)-C(11)	108.5(5)	C(19)-C(14)-C(18)	107.2(5)
C(9)-C(10)-C(11)	108.3(5)	C(15)-C(14)-C(18)	99.3(5)
C(15)-C(10)-H(10)	109.0	C(10)-C(15)-C(14)	112.1(5)
C(9)-C(10)-H(10)	109.0	C(10)-C(15)-C(16)	119.4(5)
C(11)-C(10)-H(10)	109.0	C(14)-C(15)-C(16)	104.2(5)
C(5)-C(11)-C(12)	114.0(5)	C(10)-C(15)-H(15)	106.9
C(5)-C(11)-C(10)	110.4(5)	C(14)-C(15)-H(15)	106.9
C(12)-C(11)-C(10)	110.7(5)	C(16)-C(15)-H(15)	106.9
C(5)-C(11)-H(11)	107.1	C(15)-C(16)-C(17)	104.7(5)
C(12)-C(11)-H(11)	107.1	C(15)-C(16)-H(16A)	110.8

C(17)-C(16)-H(16A)	110.8	O(4)-C(22)-H(22C)	109.5
C(15)-C(16)-H(16B)	110.8	H(22A)-C(22)-H(22C)	109.5
C(17)-C(16)-H(16B)	110.8	H(22B)-C(22)-H(22C)	109.5
H(16A)-C(16)-H(16B)	108.9	O(4)-C(23)-C(24)	117.4(5)
C(18)-C(17)-C(16)	106.4(5)	O(4)-C(23)-C(28)	124.2(6)
C(18)-C(17)-H(17A)	110.4	C(24)-C(23)-C(28)	118.5(6)
C(16)-C(17)-H(17A)	110.4	C(25)-C(24)-C(23)	120.3(5)
C(18)-C(17)-H(17B)	110.4	C(25)-C(24)-H(24)	119.9
C(16)-C(17)-H(17B)	110.4	C(23)-C(24)-H(24)	119.9
H(17A)-C(17)-H(17B)	108.6	C(24)-C(25)-C(26)	121.8(5)
O(2)-C(18)-C(20)	110.4(6)	C(24)-C(25)-H(25)	119.1
O(2)-C(18)-C(17)	110.6(5)	C(26)-C(25)-H(25)	119.1
C(20)-C(18)-C(17)	108.6(5)	C(25)-C(26)-C(27)	118.2(5)
O(2)-C(18)-C(14)	114.0(5)	C(25)-C(26)-C(29)	122.2(5)
C(20)-C(18)-C(14)	111.1(5)	C(27)-C(26)-C(29)	119.6(5)
C(17)-C(18)-C(14)	101.7(5)	C(28)-C(27)-C(26)	119.1(5)
C(14)-C(19)-H(19A)	109.5	C(28)-C(27)-C(32)	117.7(5)
C(14)-C(19)-H(19B)	109.5	C(26)-C(27)-C(32)	123.1(5)
H(19A)-C(19)-H(19B)	109.5	C(23)-C(28)-C(27)	122.0(6)
C(14)-C(19)-H(19C)	109.5	C(23)-C(28)-H(28)	119.0
H(19A)-C(19)-H(19C)	109.5	C(27)-C(28)-H(28)	119.0
H(19B)-C(19)-H(19C)	109.5	C(26)-C(29)-C(33)	112.8(5)
C(21)-C(20)-C(18)	176.3(7)	C(26)-C(29)-C(30)	111.3(5)
C(20)-C(21)-H(21)	180.0	C(33)-C(29)-C(30)	111.7(5)
O(4)-C(22)-H(22A)	109.5	C(26)-C(29)-H(29)	106.9
O(4)-C(22)-H(22B)	109.5	C(33)-C(29)-H(29)	106.9
H(22A)-C(22)-H(22B)	109.5	C(30)-C(29)-H(29)	106.9

C(31)-C(30)-C(36)	113.0(5)	C(33)-C(34)-H(34B)	109.6
C(31)-C(30)-C(29)	109.5(5)	C(35)-C(34)-H(34B)	109.6
C(36)-C(30)-C(29)	108.1(5)	H(34A)-C(34)-H(34B)	108.1
C(31)-C(30)-H(30)	108.7	C(36)-C(35)-C(34)	108.9(5)
C(36)-C(30)-H(30)	108.7	C(36)-C(35)-C(40)	114.2(5)
C(29)-C(30)-H(30)	108.7	C(34)-C(35)-C(40)	109.2(6)
C(30)-C(31)-C(32)	109.8(5)	C(36)-C(35)-C(39)	99.1(5)
C(30)-C(31)-H(31A)	109.7	C(34)-C(35)-C(39)	116.6(5)
C(32)-C(31)-H(31A)	109.7	C(40)-C(35)-C(39)	108.7(5)
C(30)-C(31)-H(31B)	109.7	C(30)-C(36)-C(37)	119.0(5)
C(32)-C(31)-H(31B)	109.7	C(30)-C(36)-C(35)	113.4(5)
H(31A)-C(31)-H(31B)	108.2	C(37)-C(36)-C(35)	103.7(5)
C(27)-C(32)-C(31)	113.7(5)	C(30)-C(36)-H(36)	106.7
C(27)-C(32)-H(32A)	108.8	C(37)-C(36)-H(36)	106.7
C(31)-C(32)-H(32A)	108.8	C(35)-C(36)-H(36)	106.7
C(27)-C(32)-H(32B)	108.8	C(36)-C(37)-C(38)	104.9(5)
C(31)-C(32)-H(32B)	108.8	C(36)-C(37)-H(37A)	110.8
H(32A)-C(32)-H(32B)	107.7	C(38)-C(37)-H(37A)	110.8
C(29)-C(33)-C(34)	112.8(5)	C(36)-C(37)-H(37B)	110.8
C(29)-C(33)-H(33A)	109.0	C(38)-C(37)-H(37B)	110.8
C(34)-C(33)-H(33A)	109.0	H(37A)-C(37)-H(37B)	108.8
C(29)-C(33)-H(33B)	109.0	C(37)-C(38)-C(39)	105.5(5)
C(34)-C(33)-H(33B)	109.0	C(37)-C(38)-H(38A)	110.6
H(33A)-C(33)-H(33B)	107.8	C(39)-C(38)-H(38A)	110.6
C(33)-C(34)-C(35)	110.3(5)	C(37)-C(38)-H(38B)	110.6
C(33)-C(34)-H(34A)	109.6	C(39)-C(38)-H(38B)	110.6
C(35)-C(34)-H(34A)	109.6	H(38A)-C(38)-H(38B)	108.8

O(3)-C(39)-C(41)	109.0(5)	C(35)-C(40)-H(40C)	109.5
O(3)-C(39)-C(35)	115.4(6)	H(40A)-C(40)-H(40C)	109.5
C(41)-C(39)-C(35)	112.5(5)	H(40B)-C(40)-H(40C)	109.5
O(3)-C(39)-C(38)	108.4(5)	C(42)-C(41)-C(39)	178.4(8)
C(41)-C(39)-C(38)	109.1(6)	C(41)-C(42)-H(42)	180.0
C(35)-C(39)-C(38)	102.1(5)	C(2)-O(1)-C(1)	116.4(5)
C(35)-C(40)-H(40A)	109.5	C(18)-O(2)-H(2)	109.5
C(35)-C(40)-H(40B)	109.5	C(39)-O(3)-H(3)	109.5
H(40A)-C(40)-H(40B)	109.5	C(23)-O(4)-C(22)	117.8(5)



Crystal data and structure refinement:



Empirical formula	C ₆ H ₁₄ N ₀ O ₂ S ₂
Formula weight	182.29
Temperature	293(2) K
Wavelength	0.71073 Å
Crystal system	Monoclinic
Space group	P2 ₁ /c
Unit cell dimensions	a = 11.659(3) Å α = 90°. b = 4.9631(11) Å β = 103.359(3)°. c = 16.709(4) Å γ = 90°.
Volume	940.7(4) Å ³
Z	4

Density (calculated)	1.287 Mg/m ³
Absorption coefficient	0.513 mm ⁻¹
F(000)	392
Crystal size	0.220 x 0.180 x 0.170 mm ³
Theta range for data collection	2.506 to 25.010°.
Index ranges	-13<=h<=13, -5<=k<=3, -19<=l<=19
Reflections collected	5663
Independent reflections	1641 [R(int) = 0.0622]
Completeness to theta = 25.010°	99.3 %
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	1641 / 0 / 95
Goodness-of-fit on F ²	1.033
Final R indices [I>2sigma(I)]	R1 = 0.0503, wR2 = 0.1375
R indices (all data)	R1 = 0.0550, wR2 = 0.1436
Extinction coefficient	n/a
Largest diff. peak and hole	0.345 and -0.479 e.Å ⁻³

Bond lengths [Å] and angles [°]:

S(1)-C(1)	1.784(3)	C(4)-H(4)	0.9800
S(1)-C(2)	1.799(3)	C(3)-C(2)	1.520(3)
S(2)-C(6)	1.781(4)	C(3)-H(3)	0.9800
S(2)-C(5)	1.799(3)	C(2)-H(2A)	0.9700
O(1)-C(4)	1.430(3)	C(2)-H(2B)	0.9700
O(1)-H(003)	0.8200	C(5)-H(5A)	0.9700
O(2)-C(3)	1.425(2)	C(5)-H(5B)	0.9700
O(2)-H(004)	0.8200	C(1)-H(1A)	0.9600
C(4)-C(5)	1.518(3)	C(1)-H(1B)	0.9600
C(4)-C(3)	1.520(3)	C(1)-H(1C)	0.9600

C(6)-H(6A)	0.9600	C(3)-C(2)-H(2B)	108.6
C(6)-H(6B)	0.9600	S(1)-C(2)-H(2B)	108.6
C(6)-H(6C)	0.9600	H(2A)-C(2)-H(2B)	107.6
C(1)-S(1)-C(2)	100.92(14)	C(4)-C(5)-S(2)	114.97(17)
C(6)-S(2)-C(5)	100.18(14)	C(4)-C(5)-H(5A)	108.5
C(4)-O(1)-H(003)	109.5	S(2)-C(5)-H(5A)	108.5
C(3)-O(2)-H(004)	109.5	C(4)-C(5)-H(5B)	108.5
O(1)-C(4)-C(5)	108.51(18)	S(2)-C(5)-H(5B)	108.5
O(1)-C(4)-C(3)	111.07(16)	H(5A)-C(5)-H(5B)	107.5
C(5)-C(4)-C(3)	113.77(19)	S(1)-C(1)-H(1A)	109.5
O(1)-C(4)-H(4)	107.8	S(1)-C(1)-H(1B)	109.5
C(5)-C(4)-H(4)	107.8	H(1A)-C(1)-H(1B)	109.5
C(3)-C(4)-H(4)	107.8	S(1)-C(1)-H(1C)	109.5
O(2)-C(3)-C(4)	110.14(17)	H(1A)-C(1)-H(1C)	109.5
O(2)-C(3)-C(2)	105.87(16)	H(1B)-C(1)-H(1C)	109.5
C(4)-C(3)-C(2)	112.77(19)	S(2)-C(6)-H(6A)	109.5
O(2)-C(3)-H(3)	109.3	S(2)-C(6)-H(6B)	109.5
C(4)-C(3)-H(3)	109.3	H(6A)-C(6)-H(6B)	109.5
C(2)-C(3)-H(3)	109.3	S(2)-C(6)-H(6C)	109.5
C(3)-C(2)-S(1)	114.64(14)	H(6A)-C(6)-H(6C)	109.5
C(3)-C(2)-H(2A)	108.6	H(6B)-C(6)-H(6C)	109.5
S(1)-C(2)-H(2A)	108.6		



CCDC: 1892898

Crystal data and structure refinement:

Empirical formula	C11 H13 N3 O3 S
Formula weight	267.30
Temperature	173(2) K
Wavelength	1.54178 Å
Crystal system	Hexagonal
Space group	P6 ₁
Unit cell dimensions	a = 10.2409(9) Å α = 90°. b = 10.2409(9) Å β = 90°. c = 19.9884(18) Å γ = 120°.
Volume	1815.5(4) Å ³
Z	6
Density (calculated)	1.467 Mg/m ³
Absorption coefficient	2.445 mm ⁻¹
F(000)	840
Crystal size	0.190 x 0.170 x 0.160 mm ³
Theta range for data collection	4.986 to 64.762°.
Index ranges	-11 ≤ h ≤ 12, -11 ≤ k ≤ 11, -21 ≤ l ≤ 23
Reflections collected	9406
Independent reflections	1864 [R(int) = 0.0297]
Completeness to theta = 64.762°	100.0 %
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	1864 / 1 / 166
Goodness-of-fit on F ²	1.097
Final R indices [I > 2σ(I)]	R1 = 0.0264, wR2 = 0.0677
R indices (all data)	R1 = 0.0264, wR2 = 0.0677
Absolute structure parameter	0.052(6)
Extinction coefficient	0.0034(5)

Largest diff. peak and hole



0.354 and -0.253 e.Å⁻³



Bond lengths [Å] and angles [°]:



C(1)-C(2)	1.485(4)	C(11)-H(11)	0.9500
C(1)-H(1A)	0.9800	N(1)-O(1)	1.412(3)
C(1)-H(1B)	0.9800	N(2)-S(1)	1.668(2)
C(1)-H(1C)	0.9800	N(3)-H(3A)	0.8800
C(2)-C(3)	1.348(3)	N(3)-H(3B)	0.8800
C(2)-O(1)	1.351(3)	O(2)-S(1)	1.432(2)
C(3)-C(4)	1.424(3)	O(3)-S(1)	1.4274(18)
C(3)-H(3)	0.9500	C(2)-C(1)-H(1A)	109.5
C(4)-N(1)	1.313(3)	C(2)-C(1)-H(1B)	109.5
C(4)-N(2)	1.396(3)	H(1A)-C(1)-H(1B)	109.5
C(5)-C(11)	1.376(4)	C(2)-C(1)-H(1C)	109.5
C(5)-C(7)	1.395(4)	H(1A)-C(1)-H(1C)	109.5
C(5)-H(5)	0.9500	H(1B)-C(1)-H(1C)	109.5
C(6)-N(2)	1.477(3)	C(3)-C(2)-O(1)	110.1(2)
C(6)-H(6A)	0.9800	C(3)-C(2)-C(1)	133.9(2)
C(6)-H(6B)	0.9800	O(1)-C(2)-C(1)	116.0(2)
C(6)-H(6C)	0.9800	C(2)-C(3)-C(4)	104.17(19)
C(7)-C(8)	1.400(4)	C(2)-C(3)-H(3)	127.9
C(7)-S(1)	1.741(3)	C(4)-C(3)-H(3)	127.9
C(8)-C(9)	1.363(4)	N(1)-C(4)-N(2)	117.9(2)
C(8)-H(8)	0.9500	N(1)-C(4)-C(3)	111.9(2)
C(9)-C(10)	1.415(4)	N(2)-C(4)-C(3)	130.1(2)
C(9)-H(9)	0.9500	C(11)-C(5)-C(7)	120.3(2)
C(10)-N(3)	1.354(4)	C(11)-C(5)-H(5)	119.8
C(10)-C(11)	1.411(4)	C(7)-C(5)-H(5)	119.8



N(2)-C(6)-H(6A)	109.5	C(5)-C(11)-C(10)	120.9(2)
N(2)-C(6)-H(6B)	109.5	C(5)-C(11)-H(11)	119.5
H(6A)-C(6)-H(6B)	109.5	C(10)-C(11)-H(11)	119.5
N(2)-C(6)-H(6C)	109.5	C(4)-N(1)-O(1)	105.04(18)
H(6A)-C(6)-H(6C)	109.5	C(4)-N(2)-C(6)	115.7(2)
H(6B)-C(6)-H(6C)	109.5	C(4)-N(2)-S(1)	120.23(17)
C(5)-C(7)-C(8)	119.5(3)	C(6)-N(2)-S(1)	115.02(18)
C(5)-C(7)-S(1)	120.6(2)	C(10)-N(3)-H(3A)	120.0
C(8)-C(7)-S(1)	119.9(2)	C(10)-N(3)-H(3B)	120.0
C(9)-C(8)-C(7)	120.3(2)	H(3A)-N(3)-H(3B)	120.0
C(9)-C(8)-H(8)	119.8	C(2)-O(1)-N(1)	108.74(17)
C(7)-C(8)-H(8)	119.8	O(3)-S(1)-O(2)	119.37(11)
C(8)-C(9)-C(10)	121.3(2)	O(3)-S(1)-N(2)	106.66(11)
C(8)-C(9)-H(9)	119.3	O(2)-S(1)-N(2)	104.77(12)
C(10)-C(9)-H(9)	119.3	O(3)-S(1)-C(7)	109.23(12)
N(3)-C(10)-C(11)	121.2(2)	O(2)-S(1)-C(7)	108.48(12)
N(3)-C(10)-C(9)	121.2(2)	N(2)-S(1)-C(7)	107.72(11)
C(11)-C(10)-C(9)	117.6(2)		



Section S10. ^1H , ^{13}C , ^{19}F NMR spectra of the products

















































2d










2d



































































10b




172.97
 164.82
 163.43
 160.97
 138.37
 134.57
 133.70
 133.29
 130.43
 128.99
 128.30
 128.32
 127.80
 119.97
 113.26
 77.32
 76.68
 76.68
 69.60
 68.90
 51.91
 41.72
 41.10
 39.04
 26.10
 21.76
 21.69







10b-H







10b-H














































16b





16b












17b





17b











18b





18b









19b





19b










19b-H







19b-H





























22b










22b






































































31b







31b

































33d




33d







159.87
 158.64
 147.76
 147.60
 129.98
 129.88
 119.99
 119.74
 108.12
 108.09
 101.82
 101.38
 77.52
 77.00
 76.68
 67.17
 51.78
 51.75
 40.80




33d-H





122.57





33d-H












33f







33f


















































7.322
7.311
7.300
7.289
7.279
7.268
7.258
7.066
7.065
7.055
7.044
6.999
6.988
6.977
6.967




33m





148.97
128.15
121.19
120.38
77.50
77.00
76.50





33m










33m-H







33m-H










































158.08
134.27
133.19
129.94
129.94
128.39
127.90
127.90
126.79
119.48
106.51
77.32
77.00
76.68
55.32
5.85
5.81
5.81







60.96












37b









37b-H








-70.21




133.12
133.02
133.54
127.60
125.40
122.83

77.32
77.00
76.68


9.76
9.74




37c-H







-70.22



37c-H








1337.96
1337.72
1337.49
1299.62
1288.30
1277.78
1255.06


77.32
77.00
76.68

21.30


9.45
9.43



37d-H



70.00



37d-H

